Nothing Special   »   [go: up one dir, main page]

WO2010059778A1 - Procédés et compositions pour adhésion cellulaire et culture sur des substrats plans - Google Patents

Procédés et compositions pour adhésion cellulaire et culture sur des substrats plans Download PDF

Info

Publication number
WO2010059778A1
WO2010059778A1 PCT/US2009/065067 US2009065067W WO2010059778A1 WO 2010059778 A1 WO2010059778 A1 WO 2010059778A1 US 2009065067 W US2009065067 W US 2009065067W WO 2010059778 A1 WO2010059778 A1 WO 2010059778A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cell
stem cells
membrane
culture
Prior art date
Application number
PCT/US2009/065067
Other languages
English (en)
Inventor
Ya Xiong Chen
Benjamin Fryer
Original Assignee
Centocor Ortho Biotech Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41510797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010059778(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to KR1020117013831A priority Critical patent/KR101687344B1/ko
Priority to CN200980147112.7A priority patent/CN102257132B/zh
Priority to MX2011005289A priority patent/MX2011005289A/es
Priority to EP09764380.3A priority patent/EP2366022B1/fr
Priority to BRPI0921996-0A priority patent/BRPI0921996A2/pt
Priority to CA2744227A priority patent/CA2744227C/fr
Priority to JP2011537604A priority patent/JP5719305B2/ja
Application filed by Centocor Ortho Biotech Inc. filed Critical Centocor Ortho Biotech Inc.
Priority to ES09764380.3T priority patent/ES2584053T3/es
Priority to AU2009316583A priority patent/AU2009316583B2/en
Priority to RU2011124902/10A priority patent/RU2547925C2/ru
Publication of WO2010059778A1 publication Critical patent/WO2010059778A1/fr
Priority to ZA2011/04507A priority patent/ZA201104507B/en
Priority to HK12101972.6A priority patent/HK1162191A1/zh
Priority to AU2016206314A priority patent/AU2016206314B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides
    • C12N2533/78—Cellulose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Definitions

  • the present invention is directed to methods for the growth, expansion and differentiation of pluripotent stem cells on planar substrates lacking an adlayer and a feeder cell layer.
  • Vessels for mammalian cell culture and analysis involving anchorage- dependent cells are often made of glass or a polymer, such as, for example, polystyrene, that frequently requires additional surface treatment to allow the cells to attach to the surface of the vessel.
  • Such treatments may include applying an adlayer on the surface, for example, by adsorption, grafting or plasma polymerization techniques.
  • the surface treatment may be via chemical modification of the vessel surface itself, which can be achieved by, for example, atmospheric corona, radio frequency vacuum plasma, DC glow discharge, and microwave plasma treatments.
  • ES cells embryonic stem cells
  • Culture systems that employ these methods often use feeder cells or extracellular matrix proteins obtained from a different species than that of the stem cells being cultivated (xenogeneic material).
  • Media obtained by exposure to feeder cells that is, media conditioned by cells other than undifferentiated ES cells, may be used to culture the ES cells, and media may be supplemented with animal serum.
  • Reubinoff et a (Nature Biotechnol. 18:399-404, 2000) and Thompson et a (Science 282: 1145-1147, 1998) disclose the culture of ES cell lines from human blastocysts using a mouse embryonic fibroblast feeder cell layer.
  • Xu et a (Nature Biotechnology 19: 971-974, 2001) discloses the use of MATRIGEL ® and laminin for treating solid substrate surfaces before feeder-cell free cultivation of human ES cells without differentiation.
  • Valuer et a (J. Cell Sci. 118:4495-4509, 2005) discloses the use of fetal bovine serum for treating solid substrate surfaces before feeder-cell free cultivation of human ES cells without differentiation.
  • WO2005014799 discloses conditioned medium for the maintenance, proliferation and differentiation of mammalian cells.
  • Wanatabe et a (Nature Biotechnol. 35:681-686, 2007) state "a ROCK inhibitor permits survival of dissociated human embryonic stem cells", and demonstrate reduced dissociation-induced apoptosis, increases cloning efficiency (from approximately 1% to approximately 27%) and facilitation of subcloning after gene transfer, using mouse embryonic fibroblasts as feeder cells, collagen and MATRIGEL ® as extracellular matrix protein, and Y-27632 or Fasudil for inhibition of ROCK. Furthermore, dissociated human ES cells treated with Y-27632 were protected from apoptosis in serum-free suspension culture.
  • Peerani et a (EMBO Journal 26:4744-4755, 2007) state "Complexity in the spatial organization of human embryonic stem cell (hESC) cultures creates heterogeneous microenvironments (niches) that influence hESC fate.
  • hESC human embryonic stem cell
  • niches microenvironments
  • Niche size and composition regulate the balance between differentiation-inducing and -inhibiting factors.
  • a niche size-dependent spatial gradient of Smadl signaling is generated as a result of antagonistic interactions between hESCs and hESC-derived extra-embryonic endoderm (ExE).
  • Rho-GTPase has been implicated in the apoptosis of many cell types, including neurons, but the mechanism by which it acts is not fully understood.
  • Rho and ROCK in apoptosis during transplantation of embryonic stem cell-derived neural precursor cells.
  • dissociation of neural precursors activates Rho and induces apoptosis.
  • Treatment with the Rho inhibitor C3 exoenzyme and/or the ROCK inhibitor Y-27632 decreases the amount of dissociation-induced apoptosis (anoikis) by 20-30%.
  • Membrane blebbing which is an early morphological sign of apoptosis; cleavage of caspase-3; and release of cytochrome c from the mitochondria are also reduced by ROCK inhibition.
  • xenogeneic material may be unsuitable for certain applications utilizing pluripotent stem cells.
  • Alternative materials may be used.
  • Stojkovic et al. (Stem Cells 23:895-902, 2005) discloses the use of human serum for treating solid substrate surfaces before feeder-cell free cultivation of human ES cells without differentiation.
  • An alternative culture system employs serum- free medium supplemented with growth factors capable of promoting the proliferation of embryonic stem cells.
  • Cheon et al. disclose a feeder-cell free, serum-free culture system in which ES cells are maintained in unconditioned serum replacement medium supplemented with different growth factors capable of triggering ES cell self-renewal.
  • Levenstein et al. disclose methods for the long-term culture of human ES cells in the absence of fibroblasts or conditioned medium, using media supplemented with basic fibroblast growth factor (FGF).
  • FGF basic fibroblast growth factor
  • US20050148070 discloses a method of culturing human ES cells in defined media without serum and without fibroblast feeder cells, the method comprising: culturing the stem cells in a culture medium containing albumin, amino acids, vitamins, minerals, at least one transferrin or transferrin substitute, at least one insulin or insulin substitute, the culture medium essentially free of mammalian fetal serum and containing at least about 100 ng/ml of a FGF capable of activating a FGF signaling receptor, wherein the growth factor is supplied from a source other than just a fibroblast feeder layer, the medium supported the proliferation of stem cells in an undifferentiated state without feeder cells or conditioned medium.
  • US20050233446 discloses a defined media useful in culturing stem cells, including undifferentiated primate primordial stem cells.
  • the media is substantially isotonic as compared to the stem cells being cultured.
  • the particular medium comprises a base medium and an amount of each of basic FGF, insulin, and ascorbic acid necessary to support substantially undifferentiated growth of the primordial stem cells.
  • a cell culture medium for growing primate-derived primordial stem cells in a substantially undifferentiated state which includes a low osmotic pressure, low endotoxin basic medium that is effective to support the growth of primate-derived primordial stem cells.
  • the basic medium is combined with a nutrient serum effective to support the growth of primate-derived primordial stem cells and a substrate selected from the group consisting of feeder cells and an extracellular matrix component derived from feeder cells.
  • the medium further includes nonessential amino acids, an anti-oxidant, and a first growth factor selected from the group consisting of nucleosides and a pyruvate salt.”
  • US20050244962 states: "In one aspect the invention provides a method of culturing primate embryonic stem cells. One cultures the stem cells in a culture essentially free of mammalian fetal serum (preferably also essentially free of any animal serum) and in the presence of fibroblast growth factor that is supplied from a source other than just a fibroblast feeder layer. In a preferred form, the fibroblast feeder layer, previously required to sustain a stem cell culture, is rendered unnecessary by the addition of sufficient fibroblast growth factor.”
  • WO2005065354 discloses a defined, isotonic culture medium that is essentially feeder-free and serum-free, comprising: a. a basal medium; b. an amount of basic fibroblast growth factor sufficient to support growth of substantially undifferentiated mammalian stem cells; c. an amount of insulin sufficient to support growth of substantially undifferentiated mammalian stem cells; and d. an amount of ascorbic acid sufficient to support growth of substantially undifferentiated mammalian stem cells.
  • WO2005086845 discloses a method for maintenance of an undifferentiated stem cell, said method comprising exposing a stem cell to a member of the transforming growth factor-beta (TGF ⁇ ) family of proteins, a member of the fibroblast growth factor (FGF) family of proteins, or nicotinamide (NIC) in an amount sufficient to maintain the cell in an undifferentiated state for a sufficient amount of time to achieve a desired result.
  • TGF ⁇ transforming growth factor-beta
  • FGF fibroblast growth factor
  • NIC nicotinamide
  • Pluripotent stem cells provide a potential resource for research and drug screening.
  • large-scale culturing of human ES cell lines is problematic and provides substantial challenges.
  • a possible solution to these challenges is to passage and culture the human ES cells as single cells.
  • Single cells are more amenable to standard tissue culture techniques, such as, for example, counting, transfection, and the like.
  • Nicolas et al. provide a method for producing and expanding human ES cell lines from single cells that have been isolated by fluorescence-activated cell sorting following genetic modification by lentivirus vectors (Stem Cells Dev. 16: 109- 118, 2007).
  • US patent application US2005158852 discloses a method "for improving growth and survival of single human embryonic stem cells. The method includes the step of obtaining a single undifferentiated hES cell; mixing the single undifferentiated cell with an extracellular matrix to encompass the cell; and inoculating the mixture onto feeder cells with a nutrient medium in a growth environment".
  • Sidhu et al. (Stem Cells Dev. 15:61-69, 2006) describe the first report of three human ES cell clones, hES 3.1, 3.2 and 3.3, derived from the parent line hES3 by sorting of single-cell preparations by flow cytometry.
  • passage and culture of human ES cells as single cells leads to genetic abnormalities and the loss of pluripotency. Culture conditions are important in the maintenance of pluripotency and genetic stability. Generally, passage of human ES cell lines is conducted manually or with enzymatic agents such as collagenase, liberase or dispase.
  • Draper et al. note the presence of "karyotypic changes involving the gain of chromosome 17q in three independent human embryonic stem cell lines on five independent occasions.” (Nature Biotechnol. 22:53-54, 2004).
  • Mitalipova et al. state "bulk passage methods... can perpetuate aneuploid cell populations after extended passage in culture, but may be used for shorter periods (up to at least 15 passages) without compromising the karyotypes...it may be possible to maintain a normal karyotype in hES cells under long-term manual propagation conditions followed by limited bulk passaging in experiments requiring greater quantities of hES cells than manual passage methods, alone, can provide". (Nature Biotechnol. 23: 19-20, 2005).
  • Heng et al. state "the results demonstrated that the second protocol (trypsinization with gentle pipetting) is much less detrimental to cellular viability than is the first protocol (collagenase treatment with scratching). This in turn translated to higher freeze-thaw survival rates.” (Biotechnology and Applied Biochemistry 47:33-37, 2007).
  • Hasegawa et al. state "we have established hESC sublines tolerant of complete dissociation. These cells exhibit high replating efficiency and also high cloning efficiency and they maintain their ability to differentiate into the three germ layers.” (Stem Cells 24:2649-2660, 2006).
  • US Patent application 61/030,544 provides methods and compositions for cell attachment to, cultivation on and detachment from a solid substrate surface containing from at least about 0.9% nitrogen to about at least 11% nitrogen and from at least about 12% oxygen to at least about 30% oxygen, and lacking an adlayer and feeder cells.
  • the cells are treated with a compound capable of inhibiting Rho kinase activity.
  • the present invention provides methods for the growth, expansion and differentiation of pluripotent stem cells on planar substrates lacking an adlayer and a feeder cell layer, wherein the cells do not require treatment with a compound capable of inhibiting Rho kinase activity in order to bind to the planar substrate.
  • the present invention provides methods for the attachment, cultivation and differentiation of pluripotent stem cells to a planar substrate containing up to about 12% N, from at least about 12% O to at least about 55% O, a contact angle from about 18 degrees to about 32 degrees, and lacking an adlayer and a feeder cell layer.
  • Figure 1 shows the effect of the Rho kinase inhibitor H-1152 on the attachment of the human embryonic stem cell line Hl to planar substrates.
  • Panel a) depicts cell attachment on mixed cellulose ester membranes (membrane No. 2 in Table 1).
  • Panel b) depicts cell attachment on nylon membranes (membrane No. 4 in Table 1).
  • Panel c) depicts cell attachment on cellulose acetate membranes (membrane No. 5 in Table 1).
  • Panel d) depicts cell attachment on polycarbonate membranes (membrane No. 7 in Table 1).
  • Panel e) depicts cell attachment on polyethylene terephthalate membranes (membrane No. 12 in Table 1).
  • Figure 2 shows the effect of the Rho kinase inhibitor Y-26732 on the attachment of the human embryonic stem cell line H9 to mixed cellulose ester membrane (membrane No. 1 in Table 1).
  • Panel a) depicts cell attachment in a control well.
  • Panel b) depicts cell attachment for cells treated with lO ⁇ M Y-26732.
  • Panel c) depicts cell attachment for cells treated with 20 ⁇ M Y-26732.
  • Figure 3 shows the proliferation curves of the human embryonic stem cell line Hl on MATRIGEL ® coated surface (solid line) and on mixed cellulose ester membranes (membrane No. 1 in Table 1) (dashed line).
  • Figure 4 shows the G-banded chromosomes from representative cells of the human embryonic stem cells of the line Hl.
  • Panel a) depicts the chromosomes from a cell cultured on MATRIGEL ® coated surface for 10 passages.
  • Panel b) depicts the chromosomes from a cell cultured on mixed cellulose ester membranes (membrane No.1 in Table 1) for 10 passages.
  • Figure 5 shows the effect of the Rho kinase inhibitor Y26732 on cells of the human embryonic stem cell line H9 on the attachment to polycarbonate membranes (membrane No. 7 in Table 1).
  • Panel a) depicts cell attachment in a control well.
  • Panel b) depicts cell attachment following treatment with lO ⁇ M Y-26732.
  • Panel c) depicts cell attachment following treatment with 20 ⁇ M Y-26732.
  • Figure 6 shows the effect of the Rho kinase inhibitor H-1152 on the attachment of cells of the human embryonic stem cell line Hl to polycarbonate membranes (membrane No. 7 in Table 1).
  • Panel a) depicts cell attachment in a control well.
  • Figure 7 shows the detachment of cells of the human embryonic stem cell line Hl from polycarbonate membranes (membrane No. 9 in Table 1) following the removal of Rho kinase inhibitor H-1152 from the cell culture medium.
  • Figure 8 shows the effect of membrane pore size and Rho kinase inhibitor treatment on the attachment of the human embryonic stem cell line Hl to the planar substrates comprising the following: polycarbonate membrane No. 10 in Table 1 in panel a and c; and polycarbonate membrane No. 11 in Table 1 in panel b and d).
  • Panels c and d) depicts the detachment of cells when H-1152 was removed from the culture medium.
  • Figure 9 shows the maintenance of the expression of markers associated with pluripotency in cells of the human embryonic stem cell line Hl cultured on polycarbonate membranes (membrane No. 8 in Table 1) for three passages. Expression of the genes indicated in the figure was determined by real-time PCR.
  • the solid bars represent data obtained from the undifferentiated human embryonic stem cell line Hl.
  • Hashed bars represent data obtained from the cells cultured on polycarbonate membranes.
  • Figure 10 shows the ability of cells of the human embryonic stem cell line Hl to form embryoid bodies following culture for 12 passages on polycarbonate membranes (membrane No. 8 in Table 1). The figure shows representative data from a single experiment.
  • Figure 11 shows scanning electron micrographs of the planar substrates of the present invention.
  • Figure 12 shows scanning electron micrographs of the ULTRA WEBTM planar substrate.
  • Figure 13 shows the effect of the defined medium mTESRTM on the binding of cells of the human embryonic stem cell line Hl to various planar substrates.
  • Adlayer refers to a layer that is formed on a surface of a solid substrate, by attaching molecules to the surface by either covalent (also known as grafting) or non-covalent (also known as adsorption) bonds.
  • Molecules used in making an adlayer can, for example, be proteinaceous molecules, which may include, for example, extracellular matrix proteins, amino acids and the like, and non- biological molecules, such as, for example, polyethyleneimine.
  • ⁇ -cell lineage refers to cells with positive gene expression for the transcription factor PDX-I and at least one of the following transcription factors: NGN3, NKX2.2, NKX6.1, NEUROD, ISLl, HNF-3 beta, MAFA, PAX4, or PAX6.
  • Cells expressing markers characteristic of the ⁇ cell lineage include ⁇ cells.
  • Cells expressing markers characteristic of the definitive endoderm lineage refers to cells expressing at least one of the following markers: SOX17, GATA4, HNF3 beta, GSC, CERl, Nodal, FGF8, Brachyury, Mix-like homeobox protein, FGF4 CD48, eomesodermin (EOMES), DKK4, FGF 17, GATA6, CXCR4, C- Kit, CD99, or 0TX2.
  • Cells expressing markers characteristic of the definitive endoderm lineage include primitive streak precursor cells, primitive streak cells, mesendoderm cells and definitive endoderm cells.
  • Cells expressing markers characteristic of the pancreatic endoderm lineage refers to cells expressing at least one of the following markers: PDXl, HNFl beta, PTFl alpha, HNF6, NKX6.1, or HB9.
  • Cells expressing markers characteristic of the pancreatic endoderm lineage include pancreatic endoderm cells, primitive gut tube cells, and posterior foregut cells.
  • Definitive endoderm refers to cells which bear the characteristics of cells arising from the epiblast during gastrulation and which form the gastrointestinal tract and its derivatives. Definitive endoderm cells express the following markers: HNF3 beta, GAT A4, SOX 17, Cerberus, OTX2, goosecoid, C-Kit, CD99, and MIXLl.
  • Pantendocrine cell or “pancreatic hormone expressing cell”, as used herein, refers to a cell capable of expressing at least one of the following hormones: insulin, glucagon, somatostatin, and pancreatic polypeptide.
  • Extraembryonic endoderm refers to a population of cells expressing at least one of the following markers: SOX7, AFP, or SPARC.
  • Extracellular matrix proteins refers to proteinaceous molecules normally found between cells in the body or in the placenta. Extracellular matrix proteins can be derived from tissue, body fluids, such as, for example, blood, or media conditioned by non-recombinant cells or recombinant cells or bacteria.
  • Markers are nucleic acid or polypeptide molecules that are differentially expressed in a cell of interest.
  • differential expression means an increased level for a positive marker and a decreased level for a negative marker.
  • the detectable level of the marker nucleic acid or polypeptide is sufficiently higher or lower in the cells of interest compared to other cells, such that the cell of interest can be identified and distinguished from other cells using any of a variety of methods known in the art.
  • Mesendoderm cell refers to a cell expressing at least one of the following markers: CD48, eomesodermin (EOMES), SOX- 17, DKK4, HNF3 beta, GSC, FGF 17, or GATA ⁇ .
  • Pantencreatic hormone secreting cell refers to a cell capable of secreting at least one of the following hormones: insulin, glucagon, somatostatin, and pancreatic polypeptide.
  • Pre-primitive streak cell refers to a cell expressing at least one of the following markers: Nodal, or FGF8.
  • Primary streak cell refers to a cell expressing at least one of the following markers: Brachyury, Mix-like homeobox protein, or FGF4.
  • Stem cells are undifferentiated cells defined by their ability at the single cell level to both self-renew and differentiate to produce progeny cells, including self-renewing progenitors, non-renewing progenitors, and terminally differentiated cells. Stem cells are also characterized by their ability to differentiate in vitro into functional cells of various cell lineages from multiple germ layers (endoderm, mesoderm and ectoderm), as well as to give rise to tissues of multiple germ layers following transplantation and to contribute substantially to most, if not all, tissues following injection into blastocysts.
  • Stem cells are classified by their developmental potential as: (1) totipotent, meaning able to give rise to all embryonic and extraembryonic cell types; (2) pluripotent, meaning able to give rise to all embryonic cell types; (3) multipotent, meaning able to give rise to a subset of cell lineages, but all within a particular tissue, organ, or physiological system (for example, hematopoietic stem cells (HSC) can produce progeny that include HSC (self- renewal), blood cell restricted oligopotent progenitors and all cell types and elements (e.g., platelets) that are normal components of the blood); (4) oligopotent, meaning able to give rise to a more restricted subset of cell lineages than multipotent stem cells; and (5) unipotent, meaning able to give rise to a single cell lineage (e.g. , spermatogenic stem cells).
  • HSC hematopoietic stem cells
  • Differentiation is the process by which an unspecialized ("uncommitted") or less specialized cell acquires the features of a specialized cell such as, for example, a nerve cell or a muscle cell.
  • a differentiated or differentiation-induced cell is one that has taken on a more specialized ("committed") position within the lineage of a cell.
  • the term "committed”, when applied to the process of differentiation, refers to a cell that has proceeded in the differentiation pathway to a point where, under normal circumstances, it will continue to differentiate into a specific cell type or subset of cell types, and cannot, under normal circumstances, differentiate into a different cell type or revert to a less differentiated cell type.
  • De-differentiation refers to the process by which a cell reverts to a less specialized (or committed) position within the lineage of a cell.
  • the lineage of a cell defines the heredity of the cell, i.e., which cells it came from and what cells it can give rise to.
  • the lineage of a cell places the cell within a hereditary scheme of development and differentiation.
  • a lineage- specific marker refers to a characteristic specifically associated with the phenotype of cells of a lineage of interest and can be used to assess the differentiation of an uncommitted cell to the lineage of interest.
  • “Surface” as used herein refers to the outermost layer of molecules of a solid substrate vessel or matrix intended for use in cell culture or analysis.
  • the elemental composition, the roughness, and the wettability of the surface can be analyzed by X- Ray Photoelectron Spectroscopy (XPS), Atomic Force Microscopy (AFM), and contact angle measurement, respectively.
  • Maintenance refers generally to cells placed in a growth medium under conditions that facilitate cell growth and/or division that may or may not result in a larger population of the cells.
  • Passaging refers to the process of removing the cells from one culture vessel and placing them in a second culture vessel under conditions that facilitate cell growth and/or division.
  • a specific population of cells, or a cell line is sometimes referred to or characterized by the number of times it has been passaged.
  • a cultured cell population that has been passaged ten times may be referred to as a PlO culture.
  • the primary culture i.e., the first culture following the isolation of cells from tissue, is designated PO.
  • the cells are described as a secondary culture (Pl or passage 1).
  • P2 or passage 2 After the second subculture, the cells become a tertiary culture (P2 or passage 2), and so on.
  • P2 or passage 2 tertiary culture
  • the expansion of cells (i.e., the number of population doublings) during the period between passaging depends on many factors, including but not limited to the seeding density, substrate, medium, growth conditions, and time between passaging.
  • Planar substrates suitable for use in the present invention may be comprised of any material that is capable of providing a support onto which pluripotent cells may attach.
  • the planar substrate may be comprised of polycarbonate.
  • the planar substrate may be comprised of polyethylene terephthalate (PETE).
  • PETE polyethylene terephthalate
  • the planar substrate may be comprised of nylon.
  • the planar substrate may be comprised of cellulose acetate.
  • the planar substrate may be comprised of a mixed cellulose ester. Examples of planar substrates suitable for use in the present invention may be found in Table 1.
  • the present invention provides methods for the attachment, cultivation and differentiation of pluripotent stem cells to a planar substrate containing up to about 12% N, from at least about 12% O to at least about 55% O, a contact angle from about 18 degrees to about 32 degrees, and lacking an adlayer and a feeder cell layer.
  • the planar substrate containing from at least about 8% N to at least about 12% N, and from at least about 12% O to at least about 55% O may be a rough fibrous surface, or, alternatively, a smooth surface.
  • the present invention provides a method to attach pluripotent stem cells to a planar substrate containing up to about 12% N, from at least about 12% O to at least about 55% O, a contact angle from about 18 degrees to about 32 degrees, and lacking an adlayer and a feeder cell layer, comprising the steps of:
  • the pluripotent stem cells are maintained in culture after the cells attach to the surface. In one embodiment, the pluripotent stem cells are differentiated on the planar substrate after the cells attach to the surface.
  • the attachment of pluripotent stem cells to a planar substrate containing up to about 12% N, from at least about 12% O to at least about 55% O, a contact angle from about 18 degrees to about 32 degrees, and lacking an adlayer and a feeder cell layer is enhanced by treating the cells with a capable of inhibiting Rho kinase activity.
  • the compound capable of inhibiting Rho kinase activity may be removed from the cells after they have attached.
  • the compound capable of inhibiting Rho kinase activity is selected from the group consisting of: Y-27632, Fasudil, H-1152 and Hydroxyfasudil.
  • the compound capable of inhibiting Rho kinase activity may be used at a concentration from about 0.1 ⁇ M to about lOO ⁇ M. In one embodiment, the at least one compound capable of inhibiting Rho kinase activity is used at a concentration of about lO ⁇ M.
  • the elemental composition of the surface of the planar substrates of the present invention may be analysed by X-Ray Photoelectron Spectroscopy (XPS).
  • XPS also known as Electron Spectroscopy for Chemical Analysis (ESCA)
  • ESA Electron Spectroscopy for Chemical Analysis
  • the roughness of the surface of the planar substrates of the present invention may be analyzed by Atomic Force Microscopy (AFM).
  • AFM Atomic Force Microscopy
  • Surface atoms or molecules with a lateral resolution down to 1 A and a vertical resolution down to 0.1 A can be imaged by AFM.
  • the wettability of the surface of the planar substrates of the present invention may be analyzed by measuring the contact angle.
  • contact angle measurement by the static sessile drop method provides information on the interaction between the surface of a solid substrate and a liquid.
  • the contact angle describes the shape of a liquid drop resting on the surface of the solid substrate, and is the angle of contact of the liquid on the surface of the solid substrate, measured within the liquid at the contact line where liquid, solid, and gas meet.
  • a surface with a water contact angle larger than 90° is termed hydrophobic, and a surface with water contact angle less than 90° is termed hydrophilic.
  • hydrophilic On extremely hydrophilic surfaces, that is, surfaces that have a high affinity for water, a water droplet will completely spread (an effective contact angle of 0°).
  • the negative charge density of the surface of the planar substrates of the present invention may be analyzed by measuring the reactivity of the surface with crystal violet.
  • Crystal violet carries a positive charge, which enables it to bind to negatively charged molecules and parts of molecules, for example, negatively charged functional groups present on a polymer surface.
  • a surface with a high crystal violet reactivity has a higher density of negative charges than a surface with a low crystal violet reactivity, given that the surfaces have the same roughness and thus area.
  • Pluripotent stem cells may express one or more of the stage-specific embryonic antigens (SSEA) 3 and 4, and markers detectable using antibodies designated Tra-1- 60 and Tra-1-81 (Thomson et ah, Science 282: 1145, 1998). Differentiation of pluripotent stem cells in vitro results in the loss of SSEA-4, Tra- 1-60, and Tra-1-81 expression and increased expression of SSEA-I.
  • SSEA stage-specific embryonic antigens
  • Undifferentiated pluripotent stem cells typically have alkaline phosphatase activity, which can be detected by fixing the cells with 4% paraformaldehyde and then developing with Vector Red as a substrate, as described by the manufacturer (Vector Laboratories, Burlingame Calif.) Undifferentiated pluripotent stem cells also typically express OCT-4 and TERT, as detected by RT-PCR.
  • pluripotent stem cells Another desirable phenotype of propagated pluripotent stem cells is a potential to differentiate into cells of all three germinal layers: endoderm, mesoderm, and ectoderm tissues. Pluripotency of stem cells can be confirmed, for example, by injecting cells into severe combined immunodeficient (SCID) mice, fixing the teratomas that form using 4% paraformaldehyde, and then examining them histologically for evidence of cell types from the three germ layers. Alternatively, pluripotency may be determined by the creation of embryoid bodies and assessing the embryoid bodies for the presence of markers associated with the three germinal layers.
  • SCID severe combined immunodeficient
  • Propagated pluripotent stem cell lines may be karyotyped using a standard G-banding technique and compared to published karyotypes of the corresponding primate species. It is desirable to obtain cells that have a "normal karyotype,” which means that the cells are euploid, wherein all human chromosomes are present and not noticeably altered.
  • pluripotent stem cells include established lines of pluripotent cells derived from tissue formed after gestation, including pre-embryonic tissue (such as, for example, a blastocyst), embryonic tissue, or fetal tissue taken any time during gestation, typically but not necessarily before approximately 10 to 12 weeks gestation.
  • pre-embryonic tissue such as, for example, a blastocyst
  • embryonic tissue or fetal tissue taken any time during gestation, typically but not necessarily before approximately 10 to 12 weeks gestation.
  • Non-limiting examples are established lines of human embryonic stem cells or human embryonic germ cells, such as, for example the human embryonic stem cell lines Hl, H7, and H9 (WiCeIl).
  • Hl, H7, and H9 WiCeIl
  • Also contemplated is use of the compositions of this disclosure during the initial establishment or stabilization of such cells, in which case the source cells would be primary pluripotent cells taken directly from the source tissues.
  • pluripotent stem cell population already cultured in the absence of feeder cells.
  • mutant human embryonic stem cell lines such as, for example, BGOIv (BresaGen, Athens, GA).
  • pluripotent stem cells derived from non-pluripotent cells such as, for example, an adult somatic cell.
  • human embryonic stem cells are prepared as described by Thomson et al. (U.S. Pat. No. 5,843,780; Science 282: 1145, 1998; Curr. Top. Dev. Biol. 38: 133 ff., 1998; Proc. Natl. Acad. ScL U.S.A. 92:7844, 1995).
  • pluripotent stem cells are cultured on a layer of feeder cells or extracellular matrix protein that support the pluripotent stem cells in various ways, prior to culturing according to the methods of the present invention.
  • pluripotent stem cells are cultured on a feeder cell layer that supports proliferation of pluripotent stem cells without undergoing substantial differentiation.
  • the growth of pluripotent stem cells on a feeder cell layer without differentiation is supported using (i) Obtaining a culture vessel containing a feeder cell layer; and (ii) a medium conditioned by culturing previously with another cell type, or a non-conditioned medium, for example, free of serum or even chemically defined.
  • pluripotent stem cells are cultured in a culture system that is essentially free of feeder cells, but nonetheless supports proliferation of pluripotent stem cells without undergoing substantial differentiation.
  • the growth of pluripotent stem cells in feeder-cell free culture without differentiation is supported using (i) an adlayer on a solid substrate surface with one or more extracellular matrix proteins; and (ii) a medium conditioned by culturing previously with another cell type, or a non-conditioned medium, for example, free of serum or even chemically defined.
  • pluripotent stem cells are cultured on a planar surface comprising a mixed cellulose ester in a medium conditioned by culturing previously with another cell type, or a non-conditioned medium, for example, free of serum or even chemically defined.
  • Culture medium An example of cell culture medium suitable for use in the present invention may be found in US20020072117. Another example of cell culture medium suitable for use in the present invention may be found in US6642048. Another example of cell culture medium suitable for use in the present invention may be found in WO2005014799. Another example of cell culture medium suitable for use in the present invention may be found in Xu et al (Stem Cells 22: 972-980, 2004). Another example of cell culture medium suitable for use in the present invention may be found in US20070010011. Another example of cell culture medium suitable for use in the present invention may be found in Cheon et al. (BioReprod
  • Another example of cell culture medium suitable for use in the present invention may be found in Levenstein et al. (Stem Cells 24: 568-574, 2006).
  • Another example of cell culture medium suitable for use in the present invention may be found in US20050148070.
  • Another example of cell culture medium suitable for use in the present invention may be found in US20050233446.
  • Another example of cell culture medium suitable for use in the present invention may be found in US6800480.
  • Another example of cell culture medium suitable for use in the present invention may be found in US20050244962.
  • Another example of cell culture medium suitable for use in the present invention may be found in WO2005065354.
  • Another example of cell culture medium suitable for use in the present invention may be found in WO2005086845.
  • Suitable culture media may also be made from the following components, such as, for example, Dulbecco's modified Eagle's medium (DMEM), Gibco # 11965-092; Knockout Dulbecco's modified Eagle's medium (KO DMEM), Gibco # 10829-018; Ham's F12/50% DMEM basal medium; 200 mM L-glutamine, Gibco # 15039-027; non-essential amino acid solution, Gibco 11140-050; ⁇ -mercaptoethanol, Sigma # M7522; human recombinant basic fibroblast growth factor (bFGF), Gibco # 13256- 029.
  • DMEM Dulbecco's modified Eagle's medium
  • KO DMEM Knockout Dulbecco's modified Eagle's medium
  • Ham's F12/50% DMEM basal medium 200 mM L-glutamine, Gibco # 15039-027; non-essential amino acid solution, Gibco 11140-050; ⁇ -mercapto
  • pluripotent stem cells are propagated in culture, while maintaining their pluripotency. Changes in pluripotency of the cells with time can be determined by detecting changes in the levels of expression of markers associated with pluripotency. Alternatively, changes in pluripotency can be monitored by detecting changes in the levels of expression of markers associated with differentiation or markers associated with another cell type.
  • pluripotent stem cells are propagated in culture and then treated in a manner that promotes their differentiation into another cell type.
  • the other cell type may be a cell expressing markers characteristic of the definitive endoderm lineage.
  • the cell type may be a cell expressing markers characteristic of the pancreatic endoderm lineage.
  • the cell type may be a cell expressing markers characteristic of the pancreatic endocrine lineage.
  • the cell type may be a cell expressing markers characteristic of the ⁇ - cell lineage.
  • Pluripotent stem cells treated in accordance with the methods of the present invention may be differentiated into a variety of other cell types by any suitable method in the art.
  • pluripotent stem cells treated in accordance with the methods of the present invention may be differentiated into neural cells, cardiac cells, hepatocytes, and the like.
  • pluripotent stem cells treated in accordance with the methods of the present invention may be differentiated into neural progenitors and cardiomyocytes according to the methods disclosed in WO2007030870.
  • pluripotent stem cells treated in accordance with the methods of the present invention may be differentiated into hepatocytes according to the methods disclosed in US patent 6,458,589.
  • pluripotent stem cells may be differentiated into cells expressing markers characteristic of the definitive endoderm lineage according to the methods disclosed in D'Amour et ah, Nature Biotechnol. 23: 1534-1541, 2005.
  • pluripotent stem cells may be differentiated into cells expressing markers characteristic of the definitive endoderm lineage according to the methods disclosed in Shinozaki et ah, Development 131 : 1651-1662, 2004.
  • pluripotent stem cells may be differentiated into cells expressing markers characteristic of the definitive endoderm lineage according to the methods disclosed in McLean et ah, Stem Cells 25:29-38, 2007.
  • pluripotent stem cells may be differentiated into cells expressing markers characteristic of the definitive endoderm lineage according to the methods disclosed in D'Amour et ah, Nature Biotechnol. 24: 1392-1401, 2006.
  • Markers characteristic of the definitive endoderm lineage are selected from the group consisting of SOX17, GATA4, HNF3 beta, GSC, CERl, Nodal, FGF8, Brachyury, Mix-like homeobox protein, FGF4 CD48, eomesodermin (EOMES), DKK4, FGF 17, GATA6, CXCR4, C-Kit, CD99, and OTX2.
  • Suitable for use in the present invention is a cell that expresses at least one of the markers characteristic of the definitive endoderm lineage.
  • a cell expressing markers characteristic of the definitive endoderm lineage is a primitive streak precursor cell.
  • a cell expressing markers characteristic of the definitive endoderm lineage is a mesendoderm cell.
  • a cell expressing markers characteristic of the definitive endoderm lineage is a definitive endoderm cell.
  • pluripotent stem cells may be differentiated into cells expressing markers characteristic of the pancreatic endoderm lineage according to the methods disclosed in D'Amour et ah, Nature Biotechnol. 24: 1392-1401, 2006.
  • Markers characteristic of the pancreatic endoderm lineage are selected from the group consisting of PDXl, HNFl beta, PTFl alpha, HNF6, HB9 and PROXl.
  • Suitable for use in the present invention is a cell that expresses at least one of the markers characteristic of the pancreatic endoderm lineage.
  • a cell expressing markers characteristic of the pancreatic endoderm lineage is a pancreatic endoderm cell.
  • Pluripotent stem cells may be differentiated into cells expressing markers characteristic of the pancreatic endocrine lineage by any method in the art.
  • pluripotent stem cells may be differentiated into cells expressing markers characteristic of the pancreatic endocrine lineage according to the methods disclosed in D'Amour et ah, Nature Biotechnol. 24: 1392-1401, 2006.
  • pluripotent stem cells may be differentiated into cells expressing markers characteristic of the pancreatic endocrine lineage, by the methods disclosed in D'Amour et a ⁇ ., Nature Biotechnol. 24: 1392-1401, 2006.
  • a pancreatic endocrine cell is capable of expressing at least one of the following hormones: insulin, glucagon, somatostatin, and pancreatic polypeptide.
  • Suitable for use in the present invention is a cell that expresses at least one of the markers characteristic of the pancreatic endocrine lineage.
  • a cell expressing markers characteristic of the pancreatic endocrine lineage is a pancreatic endocrine cell.
  • the pancreatic endocrine cell may be a pancreatic hormone-expressing cell.
  • the pancreatic endocrine cell may be a pancreatic hormone-secreting cell.
  • the pancreatic endocrine cell is a cell expressing markers characteristic of the ⁇ cell lineage.
  • a cell expressing markers characteristic of the ⁇ cell lineage expresses PDXl and at least one of the following transcription factors: NGN3, NKX2.2, NKX6.1, NEUROD, ISLl, HNF3 beta, MAFA, PAX4, and PAX6.
  • a cell expressing markers characteristic of the ⁇ cell lineage is a ⁇ cell.
  • Example 1 Attachment of Human Embryonic Stem Cells to the Planar Substrates of the Present Invention.
  • Rho kinase inhibitor Y26732 has been shown to enhance the attachment of human embryonic stem cells on surface modified plates (see U.S. Patent Application No. 61/030,544).
  • the purpose of the studies of the present invention was to determine the ability of human embryonic stem cells to attach to other planar surfaces.
  • the planar surfaces tested in the present invention are shown in Table 1.
  • cells of the human embryonic stem cell line Hl cells were expanded on tissue culture plates coated with a 1:30 dilution of growth factor-reduced MATRIGEL ® .
  • Cells were seeded onto 100 mm culture dishes in 10 ml MEF conditioned media supplemented with 20 ng/ml bFGF (MEF-CM/bFGF).
  • MEF-CM/bFGF 20 ng/ml bFGF
  • the cells were cultured at 37°C in a humidified with a 5% CO2 atmosphere.
  • the media was changed everyday with fresh MEF-CM/bFGF.
  • the cells were passaged by treatment with lmg/ml LIBERASE for 5 minutes at 37°C.
  • the digestion was stopped by removing enzyme from the dish and rinsing the cells with MEF-CM/bFGF.
  • the cells were collected by manual scraping in 10 ml MEF-CM/bFGF and transferred to a 50-ml conical tube.
  • the cells were centrifuged at 20Ox g (lOOOrpm) on a tabletop centrifuge to form a pellet. After the supernatant was removed, the cells were re-suspended in 40 ml MEF-CM/bFGF and evenly distributed in four 100 mm culture dished coated with a 1 :30 dilution of growth factor-reduced MATRIGEL ® .
  • Cells of the human embryonic stem cell line Hl were seeded onto the various planar substrates set forth in Table 1, at a density of 100,000 cells/ cm 2 .
  • the planar substrates lacked an adlayer and a fibroblast feeder cell layer.
  • the cells were cultured in MEF-CM/bFGF as described above.
  • the effect of the Rho kinase inhibitor H-1152 on the attachment of the cells to the planar substrates was determined. 3 ⁇ M H-1152 was added to the medium used to seed the cells.
  • Cells were allowed to attach for 24 hrs. After this time, the cells were fixed with 4% paraformaldehyde for 5 minutes at room temperature. The cells were then stained with 1% hematoxylin, and the number of cells was determined via light microscopy. Wells containing vehicle were included as a control.
  • the cells of the human embryonic stem cell line Hl attached to the following membranes in a Rho kinase inhibitor independent manner: mixed cellulose ester membrane (membrane No. 2, Figure 1, panel a); nylon membrane (membrane No. 4, Figure 1, panel b), and cellulose acetate membrane (membrane No. 5, Figure 1, panel c).
  • the attachment of cells to these membranes was enhanced by addition of 3 ⁇ M H- 1152 (See Figure 1, panels a-c).
  • H-1152 Cells of the human embryonic stem cell line Hl required the presence of 3 ⁇ M H-1152 to attach to the following planar substrates: Polycarbonate membrane (membrane No. 7, Figure 1, panel d) and Polyethylene terephthalate membrane (membrane No. 12, Figure 1 , panel e). Removal of H- 1152 from the culture medium led to detachment of Hl cells from both types of membranes. No attachment was observed to these membranes in the absence of H-1152.
  • Example 2 The Effect of Rho Kinase Treatment on the Attachment of Human Embryonic Stem Cells to Planar Substrates Comprising Mixed Cellulose Esters
  • Cells of the human embryonic stem cell line H9 were cultured on MATRIGEL ® coated dishes prior to experimental manipulation.
  • Cells were seeded a mixed cellulose ester membrane (membrane No. 1) at a density of 150,000 cells/ cm 2 in MEF conditioned medium.
  • the planar substrate lacked an adlayer and a fibroblast feeder cell layer.
  • the effect of the Rho Kinase inhibitor treatment on the attachment to the planar substrate was examined.
  • Cells were treated with 0, 10, or 20 ⁇ M Y26732. After 24 hours, the cells were fixed with 4% paraformaldehyde, rinsed with PBS, air dried, stained with crystal violet dye. The number of cells was determined via light microscopy. Wells containing vehicle were included as a control.
  • Example 3 The Effect of Culture on Planar Substrate Membrane No. 1 on the Proliferation Rate of Human Embryonic Stem Cells.
  • the proliferation rate of cells of the human embryonic stem cell line cultured on MATRIGEL ® coated dished and cells cultured on Membrane No. 1 was compared. Cells were seeded at equal densities on both substrates. Cells were released from the substrates by TrypLE treatment to create a single cell suspension to determine cell number. Samples of cells were taken at the times indicated in Figure 3. Cells were observed to proliferate at comparable rates. The doubling time is about 1.151 day and 1.138 day on MATRIGEL ® and on Membrane No. 1, respectively.
  • Example 4 Human Embryonic Stem Cells Maintain their Pluripotency for Three Passages on Planar Substrates Comprising Mixed Cellulose Esters
  • Cells of the human embryonic stem cell line Hl were seeded on a planar substrate comprising mixed cellulose ester membranes (membrane No. 1) at a density of 75,000 cells/cm 2 in MEF-CM containing 20ng/ml bFGF.
  • the cells were cultured for 5 or 6 days before passaging to reach approximately 75 to 90% confluency according to the methods described above. The culture medium was changed everyday. After culturing for 3 passages, the cells were collected and the expression of markers associated with pluripotency was determined by flow cytometry. As shown in Table 2, over 95% of cells maintained expression of cell surface markers associated with pluripotency, including Tral-60, Tral-81, SSEA-3, and SSEA-4, indicating the cells were still pluripotent.
  • Example 5 Human Embryonic Stem Cells Maintain a Stable Karyotype for Ten Passages on Planar Substrates Comprising Mixed Cellulose Esters (Membrane).
  • Cells of the human embryonic stem cell line Hl were cultured either on MATRIGEL ® coated culture plates or on mixed cellulose esters membrane for 10 passages. The cells were cultured according to the methods described above. The karyotype was determined by cytogenetic analysis by analyzing twenty G-banded metaphase cells. As shown in Figure 4, the G-banded chromosomes of a representative cell cultured on MATRIGEL ® coated culture plates ( Figure 4, panel a) and those of another cell cultured on mixed cellulose membrane ( Figure 4, panel b) demonstrate a normal male karyotype.
  • the karyotype was also determined by examining two hundred interphase nuclei by fluorescence in situ hybridization (FISH) using a chromosome 12p probe and a 17q probe to identify very small populations of cells with changes in chromosome 12 and 17 copy number that can not be detected by routine cytogenetics. In cells cultured on MATRIGEL ® and on mixed cellulose esters membranes, no abnormal cells with trisomy 12 and/or 17 were detected.
  • FISH fluorescence in situ hybridization
  • Example 6 Human Embryonic Stem Cells Are Able To Differentiate To Insulin- Producing Cells on Planar Substrates Comprising Mixed Cellulose Esters
  • Cells of the human embryonic stem cell line Hl were seeded on a planar substrate comprising mixed cellulose esters (Membrane No. 1) at a density of 150,000 cells/ cm 2 in MEF conditioned medium containing 20ng/ml bFGF.
  • the cells were differentiated to insulin-producing cells by treating the cells according to the differentiation protocol outlined in Table 3.
  • the cells were cultured in MEF conditioned medium containing 20ng/ml bFGF for 3 to 4 days to reach approximately 75 to 90% confluency.
  • the cells were treated in DMEM-F 12 medium containing 2% Fatty-Acid Free Bovine Serum Albumin (FAF-BSA), 100 ng/ml activin A, and 20 ng/ml Wnt3A for two days, followed by treatment with DMEM-F 12 medium, 2% Fatty -Acid Free Bovine Serum Albumin (FAF-BSA), and 100 ng/ml activin A for another two days.
  • F-BSA Fatty-Acid Free Bovine Serum Albumin
  • FAF-BSA Fatty-Acid Free Bovine Serum Albumin
  • the cells were treated in DMEM-F 12 medium containing 2% BSA, 20 ng/ml FGF7, and 250 nM Cyclopamine-KAAD for three days, followed the treatment in DMEM-F 12 medium containing 1% B27 supplement, 20 ng/ml FGF7, 250 nM Cyclopamine-KAAD, 2 ⁇ M retinoic acid (RA), and 100 ng/ml Noggin for 4 days.
  • the cells were treated in DMEM-F 12 medium containing 1% B27 supplement, 1 ⁇ M ALK5 inhibitor 2 (Axxora Cat.
  • RNA samples were collected to determine the expression of markers characteristic of the pancreatic endocrine lineage.
  • a CT number for insulin of about 17 was observed.
  • the corresponding CT value for GAPDH was about 19; these data suggests that the cells expressed high levels of insulin following treatment.
  • Example 7 Human Embryonic Stem Cells Attach to Planar Substrates Comprising Polycarbonate Membranes in a Rho Kinase Inhibitor Dependent
  • Rho Kinase inhibitor Y26732 was added to the culture medium at concentration of 0, 10, or 20 ⁇ M. After 24 hours, the cells on the membrane were fixed with 4% paraformaldehyde at room temperature, rinsed with PBS, air dried, stained with crystal violet dye. The number of cells was determined via light microscopy. Wells containing vehicle were included as a control.
  • the cells do not attach to the membrane in control dishes ( Figure 5, panel a). Addition of Y26732 resulted in the attachment of the cells on the membranes ( Figure 5, panels b and c).
  • the effect of the Rho kinase inhibitor H-1152 on the attachment of cells of the human embryonic stem cell line Hl to Membrane No. 7 was determined.
  • the cells were seeded on a planar substrate comprising polycarbonate membranes (membrane No. 7) at a density of 150,000 cells/cm 2 in MEF-CM containing 20ng/ml bFGF.
  • the Rho Kinase inhibitor H-1152 was added to the culture medium at concentration of 0, 0.03, 0.1, 0.3, 1, and 3 ⁇ M. After 24 hours, the cells on the membrane were fixed with 4% paraformaldehyde, rinsed with PBS, air dried, stained with crystal violet dye. The number of cells was determined via light microscopy. Wells containing vehicle were included as a control.
  • Cells of the human embryonic stem cell line Hl were seeded on to a planar substrate comprising polycarbonate (Membrane No. 9) at a density of 100,000 cells/ cm 2 , in MEF conditioned medium containing 20ng/ml bFGF and 3 ⁇ M of the Rho kinase inhibitor H-1152.
  • the cells were cultured for 24 hr. After this time, the culture medium was replaced with MEF conditioned medium containing 20ng/ml bFGF, lacking H-1152. After 24 hours, the cells on the membrane were fixed with 4% paraformaldehyde, rinsed with PBS, air dried, stained with crystal violet dye. The number of cells was determined via light microscopy. Wells containing H- 1152 were included as a control. Removal of H-1152 from the culture medium resulted in the detachment of cells from the planar substrate ( Figure 7).
  • Cells of the human embryonic stem cell line Hl at passage 42 were seeded onto the following planar substrates: Membrane No. 10 (pore size 0.4 ⁇ m); and Membrane No. 11 (pore size 3 ⁇ m). Cells were seeded at a density of 100,000 cells/cm 2 , in MEF conditioned medium containing 20ng/ml bFGF. The effect of Rho kinase inhibition on the attachment of the cells to the planar substrates was also examined. The cell culture medium was supplemented with .3 ⁇ M H-1152. After 24 hours, the culture medium was replaced with MEF conditioned medium containing 20ng/ml bFGF, lacking H-1152.
  • the cells on the membrane were fixed with 4% paraformaldehyde, rinsed with PBS, air dried, stained with crystal violet dye.
  • Wells containing l ⁇ M H-1152 were included as a control. The number of cells was determined via light microscopy. Wells containing vehicle were included as a control.
  • Example 10 Human Embryonic Stem Cells Maintain their Pluripotency After Multiple Passages on Planar Substrates Comprising Polycarbonate Membranes.
  • Cells of the human embryonic stem cell line Hl were seeded on to a planar substrate comprising polycarbonate membrane (Membrane No. 8). Cells were cultured in MEF conditioned medium containing 20ng/ml bFGF, supplemented with 3 ⁇ M H- 1152. The cell culture medium was changed daily. Cells were passaged by the removal of H- 1152 from the medium, and the cells were removed from the planar substrate by gentle swirling. The cells were cultured for 3 passages and collected for flow cytometry and quantitative RT-PCR analysis. As shown in Table 4, over 95% of the cells expressed cell surface markers associated with pluripotency, including Tral- 60, Tral-81, SSEA-3, and SSEA-4, as determined by flow cytometry.
  • Figure 9 shows the results of quantitative RT-PCR, indicating multiple genes expressed in the Hl cultured on polycarbonate membranes for 3 passages are at comparable levels as in undifferentiated Hl cells.
  • cells of the human embryonic stem cell line Hl were seeded on to a planar substrate comprising polycarbonate membrane (Membrane No. 8).
  • Cells were cultured in MEF conditioned medium containing 20ng/ml bFGF, supplemented with l ⁇ M H-1152. The cell culture medium was changed daily.
  • Cells were passaged by the removal of H-1152 from the medium, and the cells were removed from the planar substrate by gentle swirling.
  • the cells were cultured for 9 passages and collected for flow cytometry. As shown in Table 5, over 95% of the cells express cell surface markers associated with pluripotency, including Tral-60, Tral-81, SSEA-3, and SSEA-4.
  • An alternative method to assess pluripotency is via the ability of the cells to form embryoid bodies.
  • Cells of the human embryonic stem cell line Hl were seeded on to planar substrates comprising polycarbonate membranes (Membrane No. 8).
  • the cells were cultured in MEF conditioned medium containing 20ng/ml bFGF, supplemented with 3 ⁇ M H-1152.
  • the cell culture medium was changed daily.
  • Cells were passaged by the removal of H-1152 from the medium, and the cells were removed from the planar substrate by gentle swirling. The cells were cultured for 12 passages.
  • Embryoid body formation was achieved by the following protocol.
  • the Hl cells were collected and cultured in DMEM/F12 medium supplemented with 20% fetal bovine serum in Ultra Low Cluster Plate (Corning Cat. No: 3471).
  • the cells were fed every other day by changing 50% of the medium.
  • Embryoid bodies were formed after 14 days ( Figure 10).
  • Example 11 Human Embryonic Stem Cells are Capable of Forming Definitive Endoderm after Cultured on Planar Substrates Comprising Polycarbonate
  • Cells of the human embryonic stem cell line Hl were seeded on to a planar substrate comprising polycarbonate (Membrane No. 8).
  • the cells were initially cultured in MEF conditioned medium containing 20ng/ml bFGF, supplemented with 3 ⁇ M H- 1152.
  • the cells were then cultured in MEF conditioned medium containing 20ng/ml bFGF, supplemented with l ⁇ M H-1152 for 10 passages prior to experimental manipulation.
  • the cells were then seeded onto 100 mm tissue culture plates, coated with a 1 :30 dilution of MATRIGEL ® .
  • the cells were cultured in MEF conditioned medium containing 20ng/ml bFGF for 3 days.
  • the cells were treated in DMEM/F12, supplemented with 2% fatty acid free Bovine Serum Albumin, 100ng/ml activin A, and 20ng/ml Wnt3a for two days and then treated with DMEM/F12, supplemented with 2% fatty acid free Bovine Serum Albumin, and 100ng/ml activin A for another two days. After this time, the cells were released by TRYPLE treatment to form a single cell suspension and the expression of markers characteristic of the definitive endoderm lineage was determined by flow cytometry.
  • the surface chemistry was determined on the planar substrates of the present invention.
  • Tables 7-10 depict the X-ray Photoelectron spectroscopy (XPS) analysis and contact angle.
  • XPS X-ray Photoelectron spectroscopy
  • Membranes 1 -3 contained similar concentrations of oxygen, carbon (mainly as C-O, and C-(C 5 H), probably 0-C-O), and nitrogen (as NO 3 , NO 2 , and possibly C-N, and R 4 -N + ).
  • Membrane 3 also contained trace concentrations OfNa + and SO x and a higher concentration of C-(C 5 H).
  • the surface of membrane 6 may also contain a trace concentration of chlorine. Trace concentrations of chromium were detected only on membranes 10 and 11 5 while Na + was detected on membranes 6 - 9.
  • Figure 11 shows the scanning electron micrographs of the planar substrates of the present invention. Two types of morphologies were observed. One type was characterized by an open network of fibers. The second type was characterized by a smooth sheet with circular holes dispersed across the surface.
  • Table 10 shows the contact angle measurements from the surfaces of the present invention. Surfaces 1 through 5 had contact angle measurements from about 18° to about 32°. Pluripotent stem cells did not require the presence of an inhibitor of Rho kinase activity in order to attach to surfaces 1-5.
  • planar substrate consisting of polyamine was manufactured according to the methods disclosed in US6743273, and Schindler M et al, Biomaterials 26(28): 5624- 5631 ; 2005.
  • the planar substrate is available commercially, sold under the trademark ULTRA WEBTM.
  • ULTRA WEBTM synthetic surfaces are composed of randomly orientated electrospun polyamide nanofibers with an average fiber diameter of 280nm. The fiber size distribution is between 200 and 400nm.
  • the first ULTRA WEBTM surface tested had a slightly hydrophilic surface (catalogue #3870XXl) while the second surface, surface (catalogue #3871XX1) was slightly hydrophilic and was coated with a polyamine material which providedthe nanofibers with a free amine groups for a net positive charge. Both surfaces are highly effective at protein absorption through hydrophobic interactions. 5 micron resolution and 10,000X magnification scanning electron micrographs are shown in Figure 12. However, cells of the human embryonic stem cell line Hl were unable to attach to either of the UTRA WEBTM surfaces tested.
  • Example 14 The Effect of the use of Defined Medium on the Attachment of Pluripotent Stem Cells to the Planar Substrates of the Present Invention.
  • Cells of the human embryonic stem cell line Hl were seeded onto the following planar substrates: Membrane 1 (mixed cellulose ester), Membrane 4 (nylon), Membrane 5 (cellulose acetate) and nitrocellulose.
  • Cells were seeded at a 1:3 dilution in the defined medium mTESRTM and cultured for 24 hours. Parallel cultures un MEF-conditioned medium were included as controls. Culture of the cells in mTESRTM did not affect the ability of the cells to attach to the planar surfaces. Cells were able to attach to membranes 1, 4, and 5, and nitrocellulose.
  • the membrane that showed the greatest binding of cells using mTESRTM was Membrane 4, followed by Membrane 5, which was equal to nitrocellulose, followed by Membrane 1.
  • Table 1 Characterization of membranes suitable for use in the present invention.
  • Table 2 Expression of cell surface markers associated with pluripotency on human embryonic stem cell line Hl after propagated on mixed cellulose esters membranes for 3 passages, as determined by flow cytometry.
  • Table 3 Protocol to treat human embryonic stem cells to induce differentiation to insulin-producing cells.
  • Table 4 Expression of cell surface markers associated with pluripotency on human embryonic stem cell line Hl after cultured on polycarbonate membranes for 3 passages, as determined by flow cytometry.
  • Table 5 Expression of cell surface markers associated with pluripotency on human embryonic stem cell line Hl after propagated on polycarbonate membranes for 9 passages, as determined by flow cytometry.
  • Table 6 Expression of cell surface markers associated with definitive endoderm on human embryonic stem cell line Hl. The cells were propagated on polycarbonate membranes for 10 passages and treated for definitive endoderm differentiation.
  • Table 7 Surface Chemistry (atomic concentration in %).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La présente invention porte sur des procédés pour la croissance, le développement et la différenciation de cellules souches pluripotentes sur des substrats plans ne présentant pas de couche adsorbée et de couche de cellules nourricières.
PCT/US2009/065067 2008-11-20 2009-11-19 Procédés et compositions pour adhésion cellulaire et culture sur des substrats plans WO2010059778A1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
RU2011124902/10A RU2547925C2 (ru) 2008-11-20 2009-11-19 Способы и композиции для закрепления и культивирования клеток на плоских носителях
JP2011537604A JP5719305B2 (ja) 2008-11-20 2009-11-19 平面支持体上での細胞付着及び培養のための方法及び組成物
MX2011005289A MX2011005289A (es) 2008-11-20 2009-11-19 Metodos y composiciones para union y cultivo celular sobre sustratos planares.
EP09764380.3A EP2366022B1 (fr) 2008-11-20 2009-11-19 Procédés et compositions pour adhésion cellulaire et culture sur des substrats plans
BRPI0921996-0A BRPI0921996A2 (pt) 2008-11-20 2009-11-19 Métodos e composições para cultura e ligação de células em substratos planos.
CA2744227A CA2744227C (fr) 2008-11-20 2009-11-19 Procedes et compositions pour adhesion cellulaire et culture sur des substrats plans
ES09764380.3T ES2584053T3 (es) 2008-11-20 2009-11-19 Métodos y composiciones para la unión de células y cultivo en sustratos planos
KR1020117013831A KR101687344B1 (ko) 2008-11-20 2009-11-19 평면 기재상의 세포 부착 및 배양을 위한 방법 및 조성물
CN200980147112.7A CN102257132B (zh) 2008-11-20 2009-11-19 用于在平面基底上进行细胞附着和培养的方法和组合物
AU2009316583A AU2009316583B2 (en) 2008-11-20 2009-11-19 Methods and compositions for cell attachment and cultivation on planar substrates
ZA2011/04507A ZA201104507B (en) 2008-11-20 2011-06-17 Methods and compositions for cell attachment and cultivation on planar substrates
HK12101972.6A HK1162191A1 (zh) 2008-11-20 2012-02-27 用於在平面基底上進行細胞附著和培養的方法和組合物
AU2016206314A AU2016206314B2 (en) 2008-11-20 2016-07-21 Methods and compositions for cell attachment and cultivation on planar substrates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11645208P 2008-11-20 2008-11-20
US61/116,452 2008-11-20

Publications (1)

Publication Number Publication Date
WO2010059778A1 true WO2010059778A1 (fr) 2010-05-27

Family

ID=41510797

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/065067 WO2010059778A1 (fr) 2008-11-20 2009-11-19 Procédés et compositions pour adhésion cellulaire et culture sur des substrats plans

Country Status (15)

Country Link
US (2) US9969973B2 (fr)
EP (1) EP2366022B1 (fr)
JP (1) JP5719305B2 (fr)
KR (1) KR101687344B1 (fr)
CN (1) CN102257132B (fr)
AU (2) AU2009316583B2 (fr)
BR (1) BRPI0921996A2 (fr)
CA (1) CA2744227C (fr)
ES (1) ES2584053T3 (fr)
HK (1) HK1162191A1 (fr)
MX (1) MX2011005289A (fr)
PL (1) PL2366022T3 (fr)
RU (1) RU2547925C2 (fr)
WO (1) WO2010059778A1 (fr)
ZA (1) ZA201104507B (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014027176A2 (fr) * 2012-08-17 2014-02-20 Keele University Procédé de culture de cellules souches
US9345486B2 (en) 2009-03-16 2016-05-24 University Of Washington Nanofibrous conduits for nerve regeneration
US10190096B2 (en) 2014-12-18 2019-01-29 President And Fellows Of Harvard College Methods for generating stem cell-derived β cells and uses thereof
US10253298B2 (en) 2014-12-18 2019-04-09 President And Fellows Of Harvard College Methods for generating stem cell-derived beta cells and methods of use thereof
US10443042B2 (en) 2014-12-18 2019-10-15 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived beta cells and uses thereof
US10655106B2 (en) 2013-06-11 2020-05-19 President And Fellows Of Harvard College SC-beta cells and compositions and methods for generating the same
US11466256B2 (en) 2018-08-10 2022-10-11 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
US11945795B2 (en) 2017-11-15 2024-04-02 Vertex Pharmaceuticals Incorporated Islet cell manufacturing compositions and methods of use

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI125965B (en) 2012-09-25 2016-04-29 Upm Kymmene Corp Three-dimensional cell culture
CN103031270A (zh) * 2013-01-05 2013-04-10 绍兴文理学院 胆管上皮细胞的高效扩增和培养方法
WO2019102593A1 (fr) * 2017-11-24 2019-05-31 株式会社Ihi Dispositif de culture cellulaire

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008035110A1 (fr) * 2006-09-22 2008-03-27 Riken Milieu de culture de cellules souches et procédé
WO2009105570A2 (fr) * 2008-02-21 2009-08-27 Centocor Ortho Biotech Inc. Procédés, plaques à surface modifiée et compositions permettant la fixation, la culture et le détachement de cellules

Family Cites Families (249)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3209652A (en) * 1961-03-30 1965-10-05 Burgsmueller Karl Thread whirling method
AT326803B (de) * 1968-08-26 1975-12-29 Binder Fa G Maschenware sowie verfahren zur herstellung derselben
US3935067A (en) * 1974-11-22 1976-01-27 Wyo-Ben Products, Inc. Inorganic support for culture media
CA1201400A (fr) 1982-04-16 1986-03-04 Joel L. Williams Surfaces chimiquement specifiques pour influencer l'activite cellulaire pendant la culture
US4499802A (en) * 1982-09-29 1985-02-19 Container Graphics Corporation Rotary cutting die with scrap ejection
US4537773A (en) * 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
US4557264A (en) * 1984-04-09 1985-12-10 Ethicon Inc. Surgical filament from polypropylene blended with polyethylene
US5215893A (en) * 1985-10-03 1993-06-01 Genentech, Inc. Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US5089396A (en) * 1985-10-03 1992-02-18 Genentech, Inc. Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US4737578A (en) * 1986-02-10 1988-04-12 The Salk Institute For Biological Studies Human inhibin
US5863531A (en) * 1986-04-18 1999-01-26 Advanced Tissue Sciences, Inc. In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
US5759830A (en) * 1986-11-20 1998-06-02 Massachusetts Institute Of Technology Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo
CA1340581C (fr) * 1986-11-20 1999-06-08 Joseph P. Vacanti Neomorphogenese chimerique d'organes par implatation cellulaire controlee, utilisant des matrices artificielles
US5567612A (en) * 1986-11-20 1996-10-22 Massachusetts Institute Of Technology Genitourinary cell-matrix structure for implantation into a human and a method of making
NZ229354A (en) 1988-07-01 1990-09-26 Becton Dickinson Co Treating polymer surfaces with a gas plasma and then applying a layer of endothelial cells to the surface
EP0363125A3 (fr) 1988-10-03 1990-08-16 Hana Biologics Inc. Produit contenant des cellules pancréatiques endocrines aptes à proliférer et procédé
US5837539A (en) * 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
DK0628639T3 (da) 1991-04-25 2000-01-24 Chugai Pharmaceutical Co Ltd Rekonstitueret humant antistof mod human interleukin-6-receptor
US5449383A (en) * 1992-03-18 1995-09-12 Chatelier; Ronald C. Cell growth substrates
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
CA2114282A1 (fr) * 1993-01-28 1994-07-29 Lothar Schilder Implant multi-couches
JP3525221B2 (ja) 1993-02-17 2004-05-10 味の素株式会社 免疫抑制剤
CA2159804A1 (fr) 1993-04-08 1994-10-27 Hayden G. Coon Methode et milieu pour la culture de cellules
US5523226A (en) * 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
GB9310557D0 (en) * 1993-05-21 1993-07-07 Smithkline Beecham Plc Novel process and apparatus
TW257671B (fr) * 1993-11-19 1995-09-21 Ciba Geigy
US6001647A (en) * 1994-04-28 1999-12-14 Ixion Biotechnology, Inc. In vitro growth of functional islets of Langerhans and in vivo uses thereof
US5834308A (en) * 1994-04-28 1998-11-10 University Of Florida Research Foundation, Inc. In vitro growth of functional islets of Langerhans
US6703017B1 (en) * 1994-04-28 2004-03-09 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
JP4079461B2 (ja) 1994-12-29 2008-04-23 中外製薬株式会社 Ｉｌ−６アンタゴニストを含んでなる抗腫瘍剤の作用増強剤
US5843780A (en) * 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5718922A (en) * 1995-05-31 1998-02-17 Schepens Eye Research Institute, Inc. Intravitreal microsphere drug delivery and method of preparation
US5908782A (en) * 1995-06-05 1999-06-01 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
US5681561A (en) 1995-06-07 1997-10-28 Life Medical Sciences, Inc. Compositions and methods for improving autologous fat grafting
CN1211381C (zh) 1997-04-24 2005-07-20 奥索·麦克尼尔药品公司 用于治疗炎性疾病的取代咪唑
AU8476698A (en) * 1997-07-03 1999-01-25 Osiris Therapeutics, Inc. Human mesenchymal stem cells from peripheral blood
US6670127B2 (en) * 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
EP1015576B1 (fr) * 1997-09-16 2005-05-04 Egea Biosciences, LLC Synthese chimique complete et synthese de genes et de genomes
AU1197699A (en) * 1997-10-23 1999-05-10 Geron Corporation Methods and materials for the growth of primate-derived primordial stem cells
US6372779B1 (en) * 1997-12-29 2002-04-16 Ortho Pharmaceutical Corporation Anti-inflammatory compounds
ATE316795T1 (de) * 1998-03-18 2006-02-15 Osiris Therapeutics Inc Mesenchymale stammzellen für die prävention und behandlung von immunantworten bei transplantationen
MY132496A (en) * 1998-05-11 2007-10-31 Vertex Pharma Inhibitors of p38
US6413773B1 (en) 1998-06-01 2002-07-02 The Regents Of The University Of California Phosphatidylinositol 3-kinase inhibitors as stimulators of endocrine differentiation
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US6667176B1 (en) * 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US6610540B1 (en) 1998-11-18 2003-08-26 California Institute Of Technology Low oxygen culturing of central nervous system progenitor cells
US6413556B1 (en) * 1999-01-08 2002-07-02 Sky High, Llc Aqueous anti-apoptotic compositions
IL144359A0 (en) * 1999-01-21 2002-05-23 Vitro Diagnostics Inc Immortalized cell lines and methods of making the same
US6815203B1 (en) * 1999-06-23 2004-11-09 Joslin Diabetes Center, Inc. Methods of making pancreatic islet cells
US6333029B1 (en) * 1999-06-30 2001-12-25 Ethicon, Inc. Porous tissue scaffoldings for the repair of regeneration of tissue
US6306424B1 (en) * 1999-06-30 2001-10-23 Ethicon, Inc. Foam composite for the repair or regeneration of tissue
AU7719300A (en) 1999-09-27 2001-04-30 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US6685936B2 (en) * 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
US20030082155A1 (en) * 1999-12-06 2003-05-01 Habener Joel F. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
JP2003517592A (ja) * 1999-12-13 2003-05-27 ザ スクリプス リサーチ インスティチュート 膵島αおよびβ前駆体の同定ならびに単離のためのマーカー
US7439064B2 (en) 2000-03-09 2008-10-21 Wicell Research Institute, Inc. Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium
US7005252B1 (en) * 2000-03-09 2006-02-28 Wisconsin Alumni Research Foundation Serum free cultivation of primate embryonic stem cells
US6436704B1 (en) * 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
US6458589B1 (en) * 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
EP1302534A4 (fr) * 2000-06-26 2004-06-16 Renomedix Inst Inc Fractions cellulaires contenant des cellules capables de se differencier en cellules neurales
PT1333833E (pt) * 2000-10-23 2011-12-09 Glaxosmithkline Llc Novo composto 8h-pirido[2,3-d]pirimidin-7-ona trissusbtituída para o tratamento de doenças mediadas por csbp/p38 cinase
ATE326464T1 (de) 2000-12-08 2006-06-15 Ortho Mcneil Pharm Inc Indazolyl-substituierte pyrrolidin-verbindungen als kinase inhibitoren
RU2275373C2 (ru) 2000-12-08 2006-04-27 Орто-Макнейл Фармасьютикал, Инк. Макрогетероциклические соединения
US6599323B2 (en) * 2000-12-21 2003-07-29 Ethicon, Inc. Reinforced tissue implants and methods of manufacture and use
CA2435826A1 (fr) * 2001-01-24 2002-08-01 The Government Of The United States Of America Differenciation de cellules souches par rapport aux ilots pancreatiques
EP2251344B2 (fr) * 2001-01-25 2024-04-24 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Formulation des composes d'acide boronique
US6656488B2 (en) * 2001-04-11 2003-12-02 Ethicon Endo-Surgery, Inc. Bioabsorbable bag containing bioabsorbable materials of different bioabsorption rates for tissue engineering
US20050054102A1 (en) * 2001-04-19 2005-03-10 Anna Wobus Method for differentiating stem cells into insulin-producing cells
DE60231035D1 (de) 2001-04-24 2009-03-19 Ajinomoto Kk Stammzellen und verfahren zu deren trennung
JP2004531262A (ja) 2001-05-15 2004-10-14 ラッパポート ファミリー インスチチュート フォア リサーチ イン ザ メディカル サイエンシズ ヒト胚性幹細胞由来インスリン産生細胞
US6626950B2 (en) * 2001-06-28 2003-09-30 Ethicon, Inc. Composite scaffold with post anchor for the repair and regeneration of tissue
KR100418195B1 (ko) 2001-07-05 2004-02-11 주식회사 우리기술 전력케이블의 다중절연진단장치 및 그 방법
GB0117583D0 (en) * 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
US7432104B2 (en) * 2001-08-06 2008-10-07 Bresgen Inc. Methods for the culture of human embryonic stem cells on human feeder cells
US6617152B2 (en) * 2001-09-04 2003-09-09 Corning Inc Method for creating a cell growth surface on a polymeric substrate
EP1298201A1 (fr) 2001-09-27 2003-04-02 Cardion AG Procédé de production de cellules présentant un état similaire à celui d'une cellule beta d'ilot pancréatique
US20050053588A1 (en) * 2001-10-18 2005-03-10 Li Yin Conversion of liver stem and progenitor cells to pancreatic functional cells
CA2468171C (fr) 2001-11-15 2015-10-06 Children's Medical Center Corporation Techniques d'isolation, de developpement et de differenciation de cellules souches provenant de villosites choriales, de liquide amniotique ainsi que de placenta et applications therapeutiques
CA2692325C (fr) * 2001-12-07 2015-10-20 Geron Corporation Cellules d'ilots pancreatiques provenant de cellules souches embryonnaires humaines
CN1630526B (zh) * 2001-12-07 2010-05-05 马克罗珀尔生物外科公司 用加工的脂肪抽吸细胞来治疗患者的系统和方法
AU2002218893A1 (en) 2001-12-21 2003-07-09 Thromb-X Nv Compositions for the in vitro derivation and culture of embryonic stem (es) cell lines with germline transmission capability
GB2398795A (en) 2001-12-28 2004-09-01 Cellartis Ab A method for the establishment of a pluripotent human blastocyst-derived stem cell line
US20030162290A1 (en) 2002-01-25 2003-08-28 Kazutomo Inoue Method for inducing differentiation of embryonic stem cells into functioning cells
US20030180268A1 (en) 2002-02-05 2003-09-25 Anthony Atala Tissue engineered construct for supplementing or replacing a damaged organ
JPWO2003087349A1 (ja) * 2002-04-17 2005-08-18 大塚製薬株式会社 間葉系細胞から膵β細胞を形成する方法
US20040161419A1 (en) * 2002-04-19 2004-08-19 Strom Stephen C. Placental stem cells and uses thereof
ATE387444T1 (de) 2002-05-08 2008-03-15 Janssen Pharmaceutica Nv Substituierte pyrroline als kinase inhibitoren
US20060003446A1 (en) * 2002-05-17 2006-01-05 Gordon Keller Mesoderm and definitive endoderm cell populations
AU2003228255A1 (en) 2002-05-28 2003-12-19 Becton, Dickinson And Company Pancreatic acinar cells into insulin-producing cells
EP1513830A1 (fr) * 2002-06-05 2005-03-16 Janssen Pharmaceutica N.V. Derives de bisindolyl-maleimide utilises en tant qu'inhibiteurs de kinase
GB0212976D0 (en) 2002-06-06 2002-07-17 Tonejet Corp Pty Ltd Ejection method and apparatus
CN1171991C (zh) 2002-07-08 2004-10-20 徐如祥 人神经干细胞的培养方法
US6877147B2 (en) * 2002-07-22 2005-04-05 Broadcom Corporation Technique to assess timing delay by use of layout quality analyzer comparison
US7838290B2 (en) * 2002-07-25 2010-11-23 The Scripps Research Institute Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
JP2005534345A (ja) 2002-07-29 2005-11-17 エス セル インターナショナル ピーティーイー リミテッド インスリン陽性、グルコース応答性細胞の分化のための多段階方法
US20040063204A1 (en) 2002-08-14 2004-04-01 Lijun Yang Bone marrow cell differentiation
AU2003268534A1 (en) 2002-09-06 2004-03-29 Amcyte Inc. Cd56 positive human adult pancreatic endocrine progenitor cells
US9969977B2 (en) * 2002-09-20 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
US20040062753A1 (en) * 2002-09-27 2004-04-01 Alireza Rezania Composite scaffolds seeded with mammalian cells
US20040078090A1 (en) * 2002-10-18 2004-04-22 Francois Binette Biocompatible scaffolds with tissue fragments
AU2003285172A1 (en) 2002-11-08 2004-06-03 The Johns Hopkins University Human embryonic stem cell cultures, and compositions and methods for growing same
US7144999B2 (en) * 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
AU2003302702B2 (en) 2002-12-05 2008-08-07 Technion Research & Development Foundation Ltd. Cultured human pancreatic islets, and uses thereof
WO2004055155A2 (fr) 2002-12-16 2004-07-01 Technion Research & Development Foundation Ltd. Procedes pour preparer des cellules souches embryonnaires humaines exemptes de cellules nourricieres et de xeno-contaminants et cultures de cellules souches preparees au moyen de ces procedes
PL377403A1 (pl) 2003-01-29 2006-02-06 Takeda Pharmaceutical Company Limited Sposób wytwarzania preparatu powlekanego
RU2359671C2 (ru) 2003-01-29 2009-06-27 Такеда Фармасьютикал Компани Лимитед Способ получения препарата с покрытием
WO2004073633A2 (fr) 2003-02-14 2004-09-02 The Board Of Trustees Of The Leland Stanford Junior University Methodes et compositions permettant de moduler le developpement de cellules souches
WO2005045001A2 (fr) 2003-02-14 2005-05-19 The Board Of Trustees Of The Leland Stanford Junior University Cellules produisant de l'insuline derivees de cellules souches
US20070020242A1 (en) 2003-03-27 2007-01-25 Ixion Biotechnology, Inc. Method for transdifferentiation of non-pancreatic stem cells to the pancreatic pathway
US20060194315A1 (en) * 2003-03-31 2006-08-31 Condie Brian G Compositions and methods for the control, differentiaton and/or manipulation of pluripotent cells through a gamma-secretase signaling pathway
US20090203141A1 (en) 2003-05-15 2009-08-13 Shi-Lung Lin Generation of tumor-free embryonic stem-like pluripotent cells using inducible recombinant RNA agents
WO2005003334A2 (fr) * 2003-06-27 2005-01-13 Ethicon, Incorporated Cellules postnatales derivees de tissu de cordon ombilical, et leur procede de production et d'utilisation
IL161903A0 (en) 2003-07-17 2005-11-20 Gamida Cell Ltd Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
ITRM20030395A1 (it) 2003-08-12 2005-02-13 Istituto Naz Per Le Malattie Infettive Lazz Terreno di coltura per il mantenimento, la proliferazione e il differenziamento di cellule di mammifero.
WO2005017117A2 (fr) 2003-08-14 2005-02-24 Martin Haas Cellules souches foetales amniotiques pluripotentes (mafsc) et constitution de banques de celles-ci
US7157275B2 (en) 2003-08-15 2007-01-02 Becton, Dickinson And Company Peptides for enhanced cell attachment and growth
AU2004269395A1 (en) 2003-08-27 2005-03-10 Stemcells California, Inc. Enriched pancreatic stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for these populations
WO2005058301A1 (fr) 2003-12-17 2005-06-30 Allergan, Inc. Procedes permettant de traiter des troubles sensibles au retinoide au moyen d'inhibiteurs selectifs de cyp26a et de cyp26b
US20060030042A1 (en) * 2003-12-19 2006-02-09 Ali Brivanlou Maintenance of embryonic stem cells by the GSK-3 inhibitor 6-bromoindirubin-3'-oxime
CN1946838A (zh) 2003-12-23 2007-04-11 赛瑟拉公司 定形内胚层
US7625753B2 (en) * 2003-12-23 2009-12-01 Cythera, Inc. Expansion of definitive endoderm cells
US20050266554A1 (en) * 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
AU2004309421B2 (en) 2003-12-23 2011-04-21 Viacyte, Inc. Definitive endoderm
WO2005065354A2 (fr) * 2003-12-31 2005-07-21 The Burnham Institute Milieu défini pour culture de cellules souches pluripotentes
TWI334443B (en) * 2003-12-31 2010-12-11 Ind Tech Res Inst Method of single cell culture of undifferentiated human embryonic stem cells
US20080241107A1 (en) 2004-01-23 2008-10-02 Copland Iii John A Methods and Compositions For Preparing Pancreatic Insulin Secreting Cells
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
US20070298453A1 (en) 2004-02-12 2007-12-27 University Of Newcastle Upon Tyne Stem Cells
JP4901471B2 (ja) 2004-02-19 2012-03-21 国立大学法人京都大学 体細胞核初期化物質のスクリーニング方法
EP1737944A4 (fr) 2004-03-09 2010-03-24 Lifescan Inc Procedes d'obtention de cellules produisant de l'insuline
WO2005086845A2 (fr) 2004-03-10 2005-09-22 Regents Of The University Of California Compositions et procedes pour faire croitre des cellules souches embryonnaires
CN1934245B (zh) 2004-03-23 2012-07-04 第一三共株式会社 多能干细胞的增殖方法
WO2005097980A2 (fr) 2004-03-26 2005-10-20 Geron Corporation Nouveau protocole de preparation d'hepatocytes a partir de cellules souches embryonnaires
AU2005230832B2 (en) 2004-04-01 2010-11-11 Wisconsin Alumni Research Foundation Differentiation of stem cells to endoderm and pancreatic lineage
CA2564114C (fr) 2004-04-27 2018-10-09 Cythera, Inc. Endoderme exprimant pdx1
CA2966883A1 (fr) 2004-07-09 2006-02-16 Cythera, Inc. Methodes d'identification de facteurs pour differencier l'endoderme definitif
MX2007001772A (es) 2004-08-13 2007-07-11 Univ Georgia Res Found Composiciones y metodos para auto-renovacion y diferenciacion de celulas troncales embrionicas humanas.
US20080268533A1 (en) 2004-08-25 2008-10-30 University Of Georgia Research Foundation, Inc. Methods and Compositions Utilizing Myc and Gsk3Beta to Manipulate the Pluripotency of Embryonic Stem Cells
DE102004043256B4 (de) 2004-09-07 2013-09-19 Rheinische Friedrich-Wilhelms-Universität Bonn Skalierbarer Prozess zur Kultivierung undifferenzierter Stammzellen in Suspension
WO2006029198A2 (fr) 2004-09-08 2006-03-16 Wisconsin Alumni Research Foundation Culture de cellules souches embryonnaires humaines
NZ553241A (en) 2004-09-08 2009-11-27 Wisconsin Alumni Res Found Medium and culture of pluripotent stem cells
US7273756B2 (en) * 2004-10-01 2007-09-25 Isto Technologies, Inc. Method for chondrocyte expansion with phenotype retention
GB2437689B (en) 2005-01-28 2009-10-28 Novathera Ltd Culture and screening methods
EP1859026A2 (fr) * 2005-01-31 2007-11-28 ES Cell International Pte Ltd. Differenciation dirigee de cellules souches embryonnaires et utilisations associees
US20060182724A1 (en) 2005-02-15 2006-08-17 Riordan Neil H Method for expansion of stem cells
WO2006094286A2 (fr) 2005-03-04 2006-09-08 John O'neil Cellules stromales adultes d'origine pancreatique
GB0505970D0 (en) 2005-03-23 2005-04-27 Univ Edinburgh Culture medium containing kinase inhibitor, and uses thereof
CN100425694C (zh) 2005-04-15 2008-10-15 北京大学 诱导胚胎干细胞向胰腺细胞分化的方法
WO2006113470A2 (fr) 2005-04-15 2006-10-26 Geron Corporation Procede pour traiter un cancer grace a l'inhibition combinee d'activites de proteasome et de telomerase
EP1874367B1 (fr) 2005-04-26 2011-07-06 Arhus Universitet Matériau biocompatible pour implants chirurgicaux et surfaces de culture cellulaire de guidage de cellules
WO2006126574A1 (fr) 2005-05-24 2006-11-30 Kumamoto University Procede d’induction de differenciation de cellule es
AU2006202209B2 (en) 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
CN101238129A (zh) 2005-06-10 2008-08-06 Irm责任有限公司 维持胚胎干细胞多能性的化合物
WO2006138433A2 (fr) 2005-06-14 2006-12-28 The Regents Of The University Of California Induction de differenciation cellulaire par des polypeptides bhlh de classe i
WO2006137787A1 (fr) 2005-06-21 2006-12-28 Ge Healthcare Bio-Sciences Ab Méthode de culture cellulaire
EP3599277A1 (fr) 2005-06-22 2020-01-29 Asterias Biotherapeutics, Inc. Culture de suspension de cellules souches embryonnaires humaines
WO2007003525A2 (fr) 2005-06-30 2007-01-11 Janssen Pharmaceutica N.V. Anilino-pyridinotriazines cycliques
US20080194021A1 (en) 2005-07-29 2008-08-14 Mays Robert W Use of a Gsk-3 Inhibitor to Maintain Potency of Culture Cells
WO2007012144A1 (fr) 2005-07-29 2007-02-01 Australian Stem Cell Centre Limited Compositions et procédés pour la croissance de cellules pluripotentes
WO2007025234A2 (fr) 2005-08-26 2007-03-01 The Trustees Of Columbia University In The City Of New York Generation de cellules endocrines pancreatiques a partir de cultures cellulaires de conduit primaire, et procedes d'utilisation pour le traitement de diabetes
WO2007026353A2 (fr) 2005-08-29 2007-03-08 Technion Research & Development Foundation Ltd. Milieux de culture de cellules souches
CN101341245A (zh) 2005-09-02 2009-01-07 新加坡科技研究局 获取祖细胞系的方法
SG151259A1 (en) 2005-09-12 2009-04-30 Es Cell Int Pte Ltd Cardiomyocyte production
WO2008048671A1 (fr) 2006-10-18 2008-04-24 University Of Illinois Cellules souches de type embryonnaire dérivées du sang périphérique d'un être humain adulte et procédés d'utilisation associés
CA2625883A1 (fr) 2005-10-14 2007-04-26 Regents Of The University Of Minnesota Differenciation de cellules souches non-embryonnaires avec des cellules possedant un phenotype pancreatique
DK2674485T3 (da) 2005-10-27 2019-08-26 Viacyte Inc Pdx-1 udtrykkende dorsal og ventral fortarm endoderm
BRPI0619794B8 (pt) 2005-12-13 2022-06-14 Univ Kyoto Uso de um fator de reprogramação, agente para a preparação de uma célula-tronco pluripotente induzida a partir de uma célula somática e métodos para preparar uma célula- tronco pluripotente induzida método e para preparar uma célula somática e uso de células-tronco pluripotentes induzidas
WO2007082963A1 (fr) 2006-01-18 2007-07-26 Fundación Instituto Valenciano De Infertilidad Lignées de cellules souches embryonnaires humaines et leurs méthodes d'utilisation
EP2420565B1 (fr) 2006-02-23 2017-08-30 ViaCyte, Inc. Compositions et procédés utiles pour cultiver des cellules différenciables
EP1999253B1 (fr) 2006-03-02 2019-05-22 Viacyte, Inc. Cellules précurseurs endocrines, cellules exprimant des hormones pancréatiques et procédés de productions associés
US7695965B2 (en) 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
WO2007127927A2 (fr) 2006-04-28 2007-11-08 Lifescan, Inc. Différentiation de cellules souches embryonnaires humaines
US8685730B2 (en) 2006-05-02 2014-04-01 Wisconsin Alumni Research Foundation Methods and devices for differentiating pluripotent stem cells into cells of the pancreatic lineage
US20070259423A1 (en) 2006-05-02 2007-11-08 Jon Odorico Method of differentiating stem cells into cells of the endoderm and pancreatic lineage
WO2007139929A2 (fr) 2006-05-25 2007-12-06 The Burnham Institute For Medical Research Procédés de culture et de production de populations de cellules isolées de cellules souches embryonnaires humaines
CN101541953A (zh) 2006-06-02 2009-09-23 佐治亚大学研究基金会 通过从人胚胎干细胞获得的定形内胚层细胞的分化得到胰和肝内胚层细胞及组织
US20090298169A1 (en) 2006-06-02 2009-12-03 The University Of Georgia Research Foundation Pancreatic and Liver Endoderm Cells and Tissue by Differentiation of Definitive Endoderm Cells Obtained from Human Embryonic Stems
US8415153B2 (en) 2006-06-19 2013-04-09 Geron Corporation Differentiation and enrichment of islet-like cells from human pluripotent stem cells
CN100494359C (zh) 2006-06-23 2009-06-03 中日友好医院 神经干细胞三维立体培养体外扩增的方法
US20080003676A1 (en) 2006-06-26 2008-01-03 Millipore Corporation Growth of embryonic stem cells
WO2008036447A2 (fr) 2006-06-26 2008-03-27 Lifescan, Inc. Culture de cellules souches pluripotentes
US8968994B2 (en) 2006-07-06 2015-03-03 Jeremy Micah Crook Method for stem cell culture and cells derived therefrom
WO2008013664A2 (fr) 2006-07-26 2008-01-31 Cythera, Inc. Procédés de production d'hormones pancréatiques
EP3441459B1 (fr) 2006-08-02 2021-03-17 Technion Research & Development Foundation Limited Procédés d'expansion de cellules souches embryonnaires dans une culture en suspension
KR101331510B1 (ko) 2006-08-30 2013-11-20 재단법인서울대학교산학협력재단 저농도의 포도당을 함유하는 인간 배아줄기세포용 배지조성물 및 이를 이용한 인간 배아 줄기세포로부터 인슐린생산 세포 또는 세포괴로 분화시키는 방법, 그리고그로부터 유도된 인슐린 생산 세포 또는 세포괴
WO2008039521A2 (fr) 2006-09-26 2008-04-03 Nmt Medical, Inc. Procédé modifiant la surface d'un implant médical pour promouvoir la croissance tissulaire
WO2008048647A1 (fr) 2006-10-17 2008-04-24 Cythera, Inc. Modulation de la voie de la phosphatidylinositol-3-kinase dans la différentiation des cellules souches embryonnaires humaines
CN101611016B (zh) 2006-10-17 2012-01-25 斯蒂菲尔实验室公司 他拉罗唑代谢物
RU2323252C1 (ru) * 2006-10-25 2008-04-27 Антонина Ивановна Колесникова Способ культивирования мезенхимальных стволовых клеток человека ex vivo
WO2008056779A1 (fr) 2006-11-09 2008-05-15 Japan As Represented By The President Of International Medical Center Of Japan Procédé destiné à la culture et au passage d'une cellule souche embryonnaire de primate, et procédé destiné à induire la différenciation de la cellule souche embryonnaire
WO2008086005A1 (fr) 2007-01-09 2008-07-17 University Of South Florida Compositions contenant de la triciribine et du bortézomib et des dérivés de ces derniers, procédés d'utilisation correspondants
KR20090115142A (ko) 2007-01-30 2009-11-04 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 초기 중배엽 세포，내배엽 및 중배엽 계통의 생성에 유용한 중내배엽 세포의 안정한 집단 및 다능성 유주 세포（ｍｍｃ）
GB0703188D0 (en) 2007-02-19 2007-03-28 Roger Land Building Large scale production of stem cells
WO2008148105A1 (fr) 2007-05-25 2008-12-04 Medistem Laboratories, Inc. Cellules souches endométriales et procédés de génération et d'utilisation de celles-ci
DK3293256T3 (da) 2007-06-29 2019-08-12 Fujifilm Cellular Dynamics Inc Automatiseret fremgangsmåde og apparatur til dyrkning af embryonale stamceller
EP3957716A1 (fr) 2007-07-18 2022-02-23 Janssen Biotech, Inc. Différenciation de cellules souches embryonnaires humaines
WO2009018453A1 (fr) 2007-07-31 2009-02-05 Lifescan, Inc. Différenciation de cellules souches embryonnaires humaines
PL2185691T3 (pl) 2007-07-31 2018-08-31 Lifescan, Inc. Różnicowanie pluripotencjalnych komórek macierzystych poprzez zastosowanie ludzkich komórek odżywczych
WO2009027644A2 (fr) 2007-08-24 2009-03-05 Stichting Het Nederlands Kanker Instituut Composition
WO2009061442A1 (fr) 2007-11-06 2009-05-14 Children's Medical Center Corporation Procédé de production de cellules souches pluripotentes induites (ips) à partir de cellules humaines non embryonnaires
EP2229434B1 (fr) 2007-11-27 2011-09-07 Lifescan, Inc. Différentiation des cellules souches embryonnaires humaines
SG154367A1 (en) 2008-01-31 2009-08-28 Es Cell Int Pte Ltd Method of differentiating stem cells
WO2009096049A1 (fr) 2008-02-01 2009-08-06 Kyoto University Cellules différenciées ayant pour origine des cellules souches pluripotentes artificielles
WO2009101407A2 (fr) 2008-02-11 2009-08-20 Cambridge Enterprise Limited Reprogrammation perfectionnée de cellules de mammifère et cellules ainsi obtenues
WO2009110215A1 (fr) 2008-03-03 2009-09-11 独立行政法人 科学技術振興機構 Procédé d'induction de différentiation de cellules ciliées
EP2479260B1 (fr) 2008-03-17 2016-01-06 Agency For Science, Technology And Research Microsupports de culture de cellules souches
RU2359030C1 (ru) 2008-03-19 2009-06-20 Общество С Ограниченной Ответственностью "Лаборатория Клеточных Технологий" Способ получения эндотелиальных клеток из эмбриональных стволовых клеток человека (варианты)
EP2727998B1 (fr) 2008-04-21 2019-06-12 Viacyte, Inc. Procédés pour la purification de cellules endodermiques pancréatiques issues de cellules souches embryonnaires humaines
US8338170B2 (en) 2008-04-21 2012-12-25 Viacyte, Inc. Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells
WO2009132083A2 (fr) 2008-04-22 2009-10-29 President And Fellows Of Harvard College Compositions et méthodes permettant de favoriser la production de cellules pancréatiques pdx1+
US7939322B2 (en) 2008-04-24 2011-05-10 Centocor Ortho Biotech Inc. Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
US20090298178A1 (en) 2008-06-03 2009-12-03 D Amour Kevin Allen Growth factors for production of definitive endoderm
DK2993226T3 (da) 2008-06-03 2021-02-22 Viacyte Inc Vækstfaktorer til fremstilling af en definitiv endoderm
US20100015711A1 (en) 2008-06-30 2010-01-21 Janet Davis Differentiation of Pluripotent Stem Cells
DE102008032236A1 (de) 2008-06-30 2010-04-01 Eberhard-Karls-Universität Tübingen Isolierung und/oder Identifizierung von Stammzellen mit adipozytärem, chondrozytärem und pankreatischem Differenzierungspotential
US20100028307A1 (en) 2008-07-31 2010-02-04 O'neil John J Pluripotent stem cell differentiation
US9683215B2 (en) 2008-08-22 2017-06-20 President And Fellows Of Harvard College Methods of reprogramming cells
CA2742268C (fr) 2008-10-31 2020-02-18 Centocor Ortho Biotech Inc. Differenciation de cellules souches embryonnaires humaines en la lignee endocrine pancreatique
CN102333862B (zh) 2008-10-31 2018-04-27 詹森生物科技公司 人胚胎干细胞向胰腺内分泌谱系的分化
US8008075B2 (en) 2008-11-04 2011-08-30 Viacyte, Inc. Stem cell aggregate suspension compositions and methods of differentiation thereof
NZ592622A (en) 2008-11-04 2012-10-26 Viacyte Inc Stem cell aggregate suspension compositions and methods for differentiation thereof
JP2012508584A (ja) 2008-11-14 2012-04-12 ヴィアサイト，インコーポレイテッド ヒト多能性幹細胞由来膵臓細胞のカプセル化
KR101774546B1 (ko) 2008-11-20 2017-09-04 얀센 바이오테크 인코포레이티드 마이크로-캐리어 상의 만능 줄기 세포 배양
EP2356218B1 (fr) 2008-12-05 2017-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé et milieu pour la différenciation neurale de cellules pluripotentes
EP2456859A4 (fr) 2009-07-20 2015-03-18 Janssen Biotech Inc Différentiation de cellules souches embryonnaires humaines
US10076544B2 (en) 2009-07-20 2018-09-18 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
AU2010319921A1 (en) 2009-10-29 2012-05-17 Janssen Biotech Inc. Pluripotent stem cells
FI20096288A0 (fi) 2009-12-04 2009-12-04 Kristiina Rajala Formulations and methods for culturing stem cells
JP6392496B2 (ja) 2009-12-23 2018-09-19 ヤンセン バイオテツク，インコーポレーテツド ヒト胚性幹細胞の分化
KR101764404B1 (ko) 2009-12-23 2017-08-03 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
WO2011108993A1 (fr) 2010-03-02 2011-09-09 National University Of Singapore Adjuvants de culture pour favoriser la prolifération des cellules souches et la réponse de différenciation
ES2893699T3 (es) 2010-03-31 2022-02-09 Scripps Research Inst Reprogramación de células
US9234170B2 (en) 2010-04-25 2016-01-12 Mount Sinai School Of Medicine Generation of anterior foregut endoderm from pluripotent cells
JP6050225B2 (ja) 2010-05-12 2016-12-21 ヤンセン バイオテツク，インコーポレーテツド ヒト胚性幹細胞の分化
JP6043999B2 (ja) 2010-08-05 2016-12-14 ウィスコンシン アラムニ リサーチ ファンデーション ヒト多能性細胞培養のための簡易基本培地
AU2011296383B2 (en) 2010-08-31 2016-03-10 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
MY177150A (en) 2011-02-28 2020-09-08 Stempeutics Res Malaysia Sdn Bhd Isolation and expansion of adult stem cells, their therapeutic composition and uses thereof
US20130274184A1 (en) 2011-10-11 2013-10-17 The Trustees Of Columbia University In The City Of New York Er stress relievers in beta cell protection
WO2013055397A1 (fr) 2011-10-14 2013-04-18 Children's Medical Center Corporation Inhibition et amélioration de la re-programmation par des enzymes de modification de la chromatine
CA2860107C (fr) 2011-12-22 2021-06-01 Janssen Biotech, Inc. Differenciation de cellules souches embryonnaires humaines en cellules positives pour l'insuline hormonales individuelles
US10519422B2 (en) 2012-02-29 2019-12-31 Riken Method of producing human retinal pigment epithelial cells
ES2897649T3 (es) 2012-06-08 2022-03-02 Janssen Biotech Inc Diferenciación de células madre embrionarias humanas en células endocrinas pancreáticas
JP6470687B2 (ja) 2012-09-03 2019-02-13 ノヴォ ノルディスク アー／エス 小分子を用いた多能性幹細胞からの膵臓内胚葉の作製
JP6557147B2 (ja) 2012-12-31 2019-08-07 ヤンセン バイオテツク，インコーポレーテツド Ｈｂ９調節物を用いたヒト胚性幹細胞の膵臓内分泌細胞への分化
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
SG10201708332WA (en) 2013-03-15 2017-11-29 Jackson Lab Isolation of non-embryonic stem cells and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008035110A1 (fr) * 2006-09-22 2008-03-27 Riken Milieu de culture de cellules souches et procédé
WO2009105570A2 (fr) * 2008-02-21 2009-08-27 Centocor Ortho Biotech Inc. Procédés, plaques à surface modifiée et compositions permettant la fixation, la culture et le détachement de cellules

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HARB NICOLE ET AL: "The Rho-Rock-Myosin Signaling Axis Determines Cell-Cell Integrity of Self-Renewing Pluripotent Stem Cells", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, SAN FRANCISCO, CA, US, vol. 3, no. 8, 1 August 2008 (2008-08-01), pages E3001 - 1, XP002530386, ISSN: 1932-6203, [retrieved on 20080801] *
KOYANAGI MASAOMI ET AL: "Inhibition of the Rho/ROCK pathway reduces apoptosis during transplantation of embryonic stem cell-derived neural precursors", JOURNAL OF NEUROSCIENCE RESEARCH, WILEY-LISS, US, vol. 86, no. 2, 1 February 2008 (2008-02-01), pages 270 - 280, XP002530383, ISSN: 0360-4012 *
PARDO A M ET AL: "Corning TM CellBIND TM Surface: An Improved Surface for Enhanced Cell Attachment(CORNING TECHNICAL REPORT 2005)", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, 1 January 2005 (2005-01-01), pages 1 - 8, XP002530385, ISSN: 0024-3205 *
VAN KOOTEN T G ET AL: "Plasma-treated polystyrene surfaces: model surfaces for studying cell-biomaterial interactions", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 25, no. 10, 1 May 2004 (2004-05-01), pages 1735 - 1747, XP004485087, ISSN: 0142-9612 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9345486B2 (en) 2009-03-16 2016-05-24 University Of Washington Nanofibrous conduits for nerve regeneration
WO2014027176A3 (fr) * 2012-08-17 2014-05-08 Keele University Procédé de culture de cellules souches
US9005607B2 (en) 2012-08-17 2015-04-14 Keele University Stem cell culture method
WO2014027176A2 (fr) * 2012-08-17 2014-02-20 Keele University Procédé de culture de cellules souches
US11104883B2 (en) 2013-06-11 2021-08-31 President And Fellows Of Harvard College SC-beta cells and compositions and methods for generating the same
US12054745B2 (en) 2013-06-11 2024-08-06 President And Fellows Of Harvard College SC-beta cells and compositions and methods for generating the same
US12049646B2 (en) 2013-06-11 2024-07-30 President And Fellows Of Harvard College SC-beta cells and compositions and methods for generating the same
US10655106B2 (en) 2013-06-11 2020-05-19 President And Fellows Of Harvard College SC-beta cells and compositions and methods for generating the same
US11162078B2 (en) 2013-06-11 2021-11-02 President And Fellows Of Harvard College SC-beta cells and compositions and methods for generating the same
US11078463B2 (en) 2013-06-11 2021-08-03 President And Fellows Of Harvard College SC-beta cells and compositions and methods for generating the same
US10253298B2 (en) 2014-12-18 2019-04-09 President And Fellows Of Harvard College Methods for generating stem cell-derived beta cells and methods of use thereof
US11085026B2 (en) 2014-12-18 2021-08-10 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived beta cells and uses thereof
US11085027B2 (en) 2014-12-18 2021-08-10 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived beta cells and uses thereof
US11085025B2 (en) 2014-12-18 2021-08-10 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived beta cells and uses thereof
US11155787B2 (en) 2014-12-18 2021-10-26 President And Fellows Of Harvard College Methods for generating stem cell-derived beta cells and methods of use thereof
US10927350B2 (en) 2014-12-18 2021-02-23 President And Fellows Of Harvard College Methods for generating stem cell-derived beta cells and uses thereof
US10443042B2 (en) 2014-12-18 2019-10-15 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived beta cells and uses thereof
US10190096B2 (en) 2014-12-18 2019-01-29 President And Fellows Of Harvard College Methods for generating stem cell-derived β cells and uses thereof
US12123023B2 (en) 2014-12-18 2024-10-22 President And Fellows Of Harvard College Methods for generating stem cell-derived β cells and methods of use thereof
US11945795B2 (en) 2017-11-15 2024-04-02 Vertex Pharmaceuticals Incorporated Islet cell manufacturing compositions and methods of use
US11466256B2 (en) 2018-08-10 2022-10-11 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
US11525120B2 (en) 2018-08-10 2022-12-13 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
US11999971B2 (en) 2018-08-10 2024-06-04 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation

Also Published As

Publication number Publication date
CN102257132B (zh) 2014-09-03
AU2009316583A1 (en) 2010-05-27
KR101687344B1 (ko) 2016-12-16
KR20110089426A (ko) 2011-08-08
BRPI0921996A2 (pt) 2015-08-18
CA2744227A1 (fr) 2010-05-27
JP5719305B2 (ja) 2015-05-13
RU2011124902A (ru) 2012-12-27
PL2366022T3 (pl) 2016-11-30
US20100124783A1 (en) 2010-05-20
US20180258387A1 (en) 2018-09-13
MX2011005289A (es) 2011-06-01
HK1162191A1 (zh) 2012-08-24
CA2744227C (fr) 2018-10-02
ES2584053T3 (es) 2016-09-23
RU2547925C2 (ru) 2015-04-10
JP2012509086A (ja) 2012-04-19
US9969973B2 (en) 2018-05-15
EP2366022B1 (fr) 2016-04-27
AU2009316583B2 (en) 2016-04-21
ZA201104507B (en) 2018-11-28
AU2016206314B2 (en) 2018-03-01
AU2016206314A1 (en) 2016-08-04
EP2366022A1 (fr) 2011-09-21
CN102257132A (zh) 2011-11-23

Similar Documents

Publication Publication Date Title
US11001802B2 (en) Surface of a vessel with polystyrene, nitrogen, oxygen and a static sessile contact angle for attachment and cultivation of cells
US20180258387A1 (en) Methods and compositions for cell attachment and cultivation on planar substrates
CA2691975C (fr) Culture de cellule souche pluripotente unique
US10316293B2 (en) Methods for producing single pluripotent stem cells and differentiation thereof
US20100087002A1 (en) Methods, Surface Modified Plates and Compositions for Cell Attachment, Cultivation and Detachment

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980147112.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09764380

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009316583

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2744227

Country of ref document: CA

Ref document number: 12011500971

Country of ref document: PH

Ref document number: MX/A/2011/005289

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011537604

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2280/KOLNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2009316583

Country of ref document: AU

Date of ref document: 20091119

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20117013831

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009764380

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011124902

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0921996

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110520